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Abstract
Cancer is largely a disease of the genome. Cancer development is thought to involve the
gradual acquisition of mutations that can activate oncogenes and/or inactivate tumor
suppressor genes, resulting in a series of genetic changes that stimulate growth, attenuate
cell death, destroy checkpoint controls, promote further genetic instability, and enable
metastasis.
In the first part of my thesis, I focused on deciphering how activation of oncogenes by
structural copy number alterations (SCNAs) that relocate enhancers in close proximity
to oncogenes can be achieved, rather than activation by mutation or amplification. This
mechanism was recently described as enhancer hijacking (EHJ). I contributed to the
understanding of the EHJ mechanism at two genomic loci, IGF2, a known oncogenic lo-
cus in colorectal cancer and IRS4, a gene identified as a top pan-cancer EHJ candidate.
To achieve this, I recapitulated the rearrangements associated with EHJ in colorectal
and lung cell lines using the CRISPR/Cas9 genomic engineering system and tested for
IGF2 and IRS4 overexpression, respectively. The rearrangements were successfully re-
constructed; however an increase in gene expression was not achieved, suggesting a more
complex mechanism of activation or context-dependency than initially anticipated. In-
vestigation of the tumor promoting role of IRS4 was supported using mouse xenografts,
where constitutive overexpression of IRS4 leads to formation of larger tumors in com-
parison to control tumors.
In the second part of this thesis I emphasized on the identification of genes, which, when
disrupted, lead to sustained cell growth and can be potential tumor suppressors. To
achieve this, I employed systematic screens on cells with different genetic backgrounds
using a combination of CRISPR/Cas9-based whole genome knockout libraries and the
powerful anchorage independent growth assay. I was able to verify known tumor sup-
pressor genes, which include components of the Hippo and mTOR pathways, as well as
to identify novel candidates including FRYL and AHR. Furthermore, a growth screen
under non-selecting conditions was performed and identified numerous candidates found
in the initial anchorage independent growth screen, which further supports the growth
promoting roles of the candidate genes. In conclusion, in my study I identified poten-
tial tumor suppressors that lead untransformed cells to enhanced as well as anchorage
independent growth.
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Zusammenfassung
Krebs ist größtenteils eine Erkrankung des Genoms. Man geht davon aus, dass sich Krebs
durch eine schrittweise Folge von Mutationen entwickelt, die über die Aktivierung von
Onkogenen und/oder Inaktivierung von Tumorsuppressorgenen schlussendlich zur Wach-
stumsstimulierung, Apoptosehemmung, Aufhebung der Checkpoint-Kontrolle, Förderung
der genetischen Instabilität und Metastasierung führt.
Im ersten Teil meiner Doktorarbeit beschäftigte ich mich mit der Frage, wie durch struk-
turelle Kopiezahlveränderungen (SCNA), durch die Enhancer in die Nähe von Onkoge-
nen verlagert werden, Onkogene aktiviert werden können. Dieser Mechanismus wurde vor
kurzem als Enhancer Hijacking (EHJ) beschrieben. Mit meiner Arbeit habe ich zum Ver-
ständnis des Mechanismus von EHJ am Beispielen zweier genomischer Loci beigetragen:
IGF2, ein bekannter onkogener Lokus in kolorektalen Tumoren und IRF4, dessen Gen
als ein Hauptkandidat für EHJ im Pan-Cancer-Kontext identifiziert wurde. Mein Ansatz
dabei war, die mit EHJ assoziierten strukturellen Rearrangierungen zu erfassen, die
in CRISPR/CAS9-editierten kolorektalen und Lungen-Krebszelllinien zur Überexprim-
ierung von IGF2 und IRS4 führen. Die Rearrangierungen wurden erfolgreich rekon-
struiert, es konnte jedoch kein Anstieg in der Genexpression festgestellt werden. Das
alles deutet darauf hin, dass ein komplexerer Aktivierungsmechanismus als ursprünglich
angenommen, verantwortlich ist oder die Ergebnisse vom Modellsystem abhängig sind.
Im Anschluss wurde die tumorpromovierende Rolle von IRS4 in einem Maus-Xenograft-
Modell herausgestellt, wobei die konstitutive Überexprimierung von IRS4 zur Entste-
hung größerer Tumore im Vergleich zur Kontrolle führt.
Im zweiten Teil meiner Arbeit lag der Fokus auf der Identifizierung von solchen Genen,
die durch genetische Veränderung zu anhaltendem Zellwachstum führen und die deshalb
potentielle Tumorssuppressoren sind. Für systematische Screens in Zellen mit unter-
schiedlichem genetischem Hintergrund wurde ein kombinierter Ansatz von CRISPR/Cas
9-basierten Whole-genome-knockout-Bibliotheken und dem verankerungsunabhängigen
Wachstumsversuch genutzt. Dabei konnte ich ein bekanntes Tumorsuppressorgen, das
Komponenten des Hippo und mTOR Pathways einschließt, bestätigen, aber auch neue
Kandidaten einschließlich FRYL andAHR identifizieren. In einem Wachstumstest unter
nichtselektiven Bedinungen wurden mehrere Kandidaten ermittelt, die im vorangegan-
genen verankerungsunabhängigen Wachstumsversuch bereits identifiziert worden sind.
iii
Dies spricht dafür, dass die Kandidatengene wachstumsfördernde Auswirkungen haben.
Zusammenfassend ergeben sich aus meinen Untersuchungen potentielle Tumorsuppres-
soren, die untransformierte Zellen zu erhöhtem wie auch verankerungsunabhängigem
Wachstum anregen.
iv
Acknowledgements
First and foremost I would like to thank my supervisor Dr. Jan Korbel who gave me the
opportunity to conduct my PhD in his laboratory. With constant encouragement and
excitement he showed me how to pursuit projects and outcoming results. He gave me the
chance to familiarize myself with the growing field of bioinformatics and its interplay with
experimental molecular biology, a strong combination in today’s science. Jan mentored,
supported and motivated me to explore and investigate various ideas during my research,
which I greatly appreciated.
Besides my supervisor, I would like to acknowledge my Thesis Advisory Committee
(TAC) members Dr. Furlong, Dr. Haering, Prof. Schiebel and Prof. Lyko who provided
me with useful comments and suggestions in every TAC meeting. These meetings played
a highly important role in the outcome of my thesis since all of them were important
decision-making timepoints. Also, I am very grateful to Dr. Jechlinger who was able to
become the first examiner for my thesis and defense in short notice.
Next, I would like to express my deep gratitude to Balca who supported me in daily bases
throughout my PhD. Balca supervised me, helped me design and conduct experiments
and introduced me to several experimental techniques. She taught me how to think
critically about my research and draw conclusions carefully. Balca vitally influenced my
development as a scientist.
Furthermore, I am grateful to Joachim, with whom I strongly collaborated in the en-
hancer hijacking project throughout most of my PhD. During numerous scientific dis-
cussions, even over a beer sometimes, we tried to figure out how to solve the mysteries
of the results we were confronted with. Working with Joachim was exciting and fun and
I gathered a lot of knowledge from his expertise.
Many thanks to Sebastian who helped me during several projects, especially when in-
volving bioinformatics. He provided many creative ideas and advice important for the
development of my work. Sebastian’s passion for science inspired me moreover to see
biological phenomenons from different angles and discuss their meaning in great detail.
Specifically I would like to thank Adrian and Benjamin who supported me throughout
many experiments, especially towards the end of my PhD. Benjamin’s thorough experi-
mental abilities helped bringing projects forward in an optimized matter. Adrian’s help,
v
support and advice cannot simply be put in a few words. He advised me how to un-
biasedly interpret results and how to correctly evaluate them. In several occasions he
pointed out when it was worth pursuing a result and when to concentrate on next steps.
Even Friday results, or “turning green” had their meaning and aside of science we had
several good laughs.
Also thanks to Charis, a friend with whom we studied together from the diploma studies
through masters up to the PhD. His cheerful and positive mood made even bad days into
a fun experience and I enjoyed the numerous serious scientific discussions about crazy
ideas of his.
I would also like to thank certain laboratory members as well as EMBL colleagues
that helped me throughout my PhD in diverse matters. Chris, Elli, George, Hernando,
Markus, Mike, Nina, Sasha, Serap, Stephanie, Ruxandra, Thomas and Tobias all played
an important role in the development of my thesis. Along with them I would like to
thank the rest of the Korbel laboratory members for stimulating scientific discussions.
I greatly appreciate the help of the EMBL facilities, such as the FACS, the Gene Core,
ALMF, IT and as well as the rest of the EMBL facilities for their great assistance when
needed.
Additionally I would like to thank my friends Flo, Michi, Nik, Ola, Hernando, Gemma,
Ana Rita and Simone for the flauben times as well as Manu, Paola, Moritz, Doro, George
and Vaso for at the great times we had together. They made life in Heidelberg a great
experience.
Furthermore I would like to express my gratitude to my family for their provided support
at any time needed. My mother Virginia and my siblings Ari and Elaine supported me
throughout my PhD. Also, I would like to thank my uncle Denis and our family friend
Jim for the scientific discussions and help especially before big presentations. Especially
I would like to thank my father who played an essential role for my development as
a scientist and as a person. The critical thinking and life values he passed on to me,
brought me where I am and will guide me to where I will continue. He will always be
remembered.
And finally I would like to thank my wife Sarah who supported me throughout my
whole PhD, who encouraged me in the difficult times and shared excitement in the
vi
positive times. She always gave me feedback when I needed it from a different scientific
perspective that stimulated my thoughts and made them more concrete. She supported
my work but also made me realize when to set it aside and take a break to enjoy activities
and trips we planned. Together now with our expected son Constantin we are looking
forward to upcoming adventures.
vii

To my family
ix

Contents
Abstract i
Acknowledgements v
Contents xi
Abbreviations xv
1 Introduction 1
1.1 Hallmarks of Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.1 Hallmarks capabilities of sustainability and tumor growth . . . . . 3
1.1.2 Cancer epistasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.1.3 Genomic alterations . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.2 Genetic Engineering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.2.1 Programmable nucleases . . . . . . . . . . . . . . . . . . . . . . . . 10
1.2.2 CRISPR/Cas9 based genetic engineering . . . . . . . . . . . . . . . 12
1.2.3 Further applications in genetic engineering . . . . . . . . . . . . . . 14
2 Recapitulating Genomic Rearrangements of IRS4 and IGF2 Impli-
cated in Enhancer Hijacking 17
2.1 Introduction and Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.1.1 Colorectal cancer analysis implicates IGF2 in enhancer hijacking . 20
2.1.2 Pan-cancer analysis implicates IRS4 in enhancer hijacking . . . . . 23
2.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.2.1 Generation of IGF2 enhancer hijacking associated rearrangements 27
2.2.2 Generation of IRS4 enhancer hijacking associated rearrangements . 30
2.2.3 Identification of IRS4 as a potential oncogene . . . . . . . . . . . . 32
2.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3 Identification of Drivers of Growth as Potential Tumor Suppressor
Genes via Genome Wide CRISPR/Cas9 Knockout Screens 41
3.1 Introduction and Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.2.1 Methodological overview . . . . . . . . . . . . . . . . . . . . . . . . 47
3.2.2 Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.2.3 Screen results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.2.4 Evaluating hits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
xi
Contents
3.2.5 Investigation of mechanism of transformation of AHR . . . . . . . 60
3.2.6 Investigation of the transformation mechanism of FRYL . . . . . . 62
3.2.7 Structural alterations in transformed cell lines . . . . . . . . . . . 63
3.2.8 Screen to identify potential growth suppressors . . . . . . . . . . . 64
3.2.9 Analysis of cancer genomes for mutational occurrence of the can-
didate genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
3.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
4 Final Conclusions 81
5 Materials and Methods 85
5.1 Experimental Procedures Related to All Chapters . . . . . . . . . . . . . . 85
5.1.1 Cell lines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.1.2 CRISPR design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.1.3 CRISPR cloning . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
5.1.4 Virus production and infection . . . . . . . . . . . . . . . . . . . . 87
5.1.5 Immunoblotting . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
5.1.6 Long-range paired-end sequencing (MP-seq) . . . . . . . . . . . . . 89
5.1.7 Mass-low coverage whole genome sequencing (LC-WGS) . . . . . . 89
5.2 Experimental Procedures Related to Chapter 2 . . . . . . . . . . . . . . . 90
5.2.1 Flow cytometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
5.2.2 IRS4 vectors and virus preparation . . . . . . . . . . . . . . . . . . 90
5.2.3 Mouse injections . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.2.4 qPCRs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.3 Experimental Procedures Related to Chapter 3 . . . . . . . . . . . . . . . 92
5.3.1 CRISPR soft-agar screen protocol . . . . . . . . . . . . . . . . . . . 92
5.3.1.1 Virus preparation . . . . . . . . . . . . . . . . . . . . . . 92
5.3.1.2 Multiplicity of infection (MOI) . . . . . . . . . . . . . . . 93
5.3.1.3 Screen and infection . . . . . . . . . . . . . . . . . . . . . 94
5.3.1.4 Agar selection . . . . . . . . . . . . . . . . . . . . . . . . 95
5.3.1.5 PCR amplification of GeCKO libraries and sequencing . . 95
5.3.2 Mapping raw representation of gRNAs and downstream analysis . 96
5.3.3 Candidate verification assay . . . . . . . . . . . . . . . . . . . . . . 97
5.3.4 MTT assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
5.3.5 Creating TP53-/- cell lines . . . . . . . . . . . . . . . . . . . . . . . 99
5.3.6 Immunofluorescence . . . . . . . . . . . . . . . . . . . . . . . . . . 99
5.3.7 Sanger sequencing verification . . . . . . . . . . . . . . . . . . . . . 100
5.3.8 Surveyor assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
5.3.9 Identification of knockout clones via Sanger sequencing . . . . . . . 101
A Appendix Related to Chapter 2 103
A.1 Additional Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
B Appendix Related to Chapter 3 105
B.1 Additional Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
xii
Contents
B.2 Additional Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Bibliography 113
xiii

Abbreviations
ANIG Anchorage Independent Growth
bp base pair
CAST Complex Alterations after Selection and Transformation
cDNA Complementary Deoxyribonucleic Acid
ChIP Chromatin Immunoprecipitation
chr Chromosome
CRISPR Clustered Regularly Interspaced Short Palindromic Repeat
DNA Deoxyribonucleic Acid
FACS Fluorescent Activated Cell Sorting
FDR False Discovery Rate
FISH Fluorescent in situ hybridization
GeCKO Genome-wide CRIPSR/CAS9 Knock-Out
GFP Green Fluorescent Protein
GI Genetic Interaction
HR Homologous Recombination
Kb Kilobase(s)
Mb Megabase(s)
MEM Mixed Effect Model
MOI Multiplicity of Infection
NHEJ Non-Homologous End Joining
PCR Polymerase Chain Reaction
PM Point Mutation
SCNA Structural Copy Number Alteration
TAD Topological Associated Domain
TALEN Transcription Activator-Like Effector Nuclease
xv
Abbreviations
TCGA The Cancer Genome Atlas
ZNF Zinc-Finger Nuclease
xvi
Chapter 1
Introduction
Throughout evolution, mammalian genomes have formed various regulatory programs
to ensure the precise development and propagation of cells in an organism. In most
multicellular organisms, including mammals, proper orchestration of these regulatory
programs are necessary to help development during which they specify cell types and
determine the body plan of the organism. Therefore, changes in the genome are a great
threat to the integrity of cell growth. To ensure that the genome is not compromised, cells
have evolved several repair mechanisms, in case errors arise. Although the regulatory
networks are redundant and robust, they can still encounter errors that jeopardize their
integrity and function. Possible layers of prevention in case of malfunction are self-
destruction, senescence or recruitment of cells that will terminate dysfunctional cells, in
order to preserve a healthy equilibrium. Even though there are many barriers preventing
a cell from going awry, there is still the possibility of failure, leading the cells to a selfish
path of uncontrolled growth. This path of cells gone astray is a disease of the genome
known as cancer.
Cancer is thought to occur through a gradual accumulation of somatic mutations result-
ing in uncontrolled cell growth (Cavenee and White, 1995). Throughout the evolution
of the cancer genome, cells find diverse ways to induce aggressive proliferation, resulting
in a large population of transformed cells, some of which will inevitably invade multiple
tissues (Martincorena and Campbell, 2015). Over a hundred different types of cancer ex-
ist, which may arise from nearly any cell type (http://www.cancer.gov/types). Although
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continuous growth is the common characteristic of all cancers, mutational processes that
affect growth are mostly different and specific for each cancer type.
Up to date there has not been any “magic bullet” to target all the different vulnerabilities
of each cancer. To better understand these, investigation of multiple mutational processes
is required. In this thesis, I investigated the mechanisms of oncogene activation by
introducing perturbations in regulatory regions around certain oncogenes. Additionally,
I sought to understand the initial steps of cancer development by identifying tumor
suppressors using an unbiased, genome-wide approach.
1.1 Hallmarks of Cancer
For a cancer cell to evolve, it needs to overcome several barriers and adopt certain non-
physiological traits. These include sustained proliferative signaling, evasion of growth
suppressors, resistance of cell death, enabling replicative immortality, induction of an-
giogenesis and activation of invasion and metastasis (Hanahan and Weinberg, 2000).
Furthermore, tumor cells will typically alter the microenvironment resulting in the pro-
motion of inflammation, the deregulation of their cellular energetics and the avoidance
of immune destruction (Hanahan and Weinberg, 2011). Genomic alterations including
point mutations (PMs) or structural variations (SVs) in tumors underlie these events
and generate the genetic diversity that enables cells to become malignant (Hanahan and
Weinberg, 2011) (Fig. 1.1).
2
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Figure 1.1: Cancer Hallmarks.
1.1.1 Hallmarks capabilities of sustainability and tumor growth
A simplistic model of tumor formation (tumorigenesis) is caused by defects in tumor sup-
pressors or proto-oncogenes. Tumor suppressors are important to restrain uncontrolled
growth whereas oncogenes (altered proto-oncogenes by mutation causing constitutive
activation) perform the opposite: they promote growth. Both tumor suppressors and
oncogenes act on various layers of cell regulation, which effect different cancer hallmarks.
Strategies to investigate the cancer roles of genes include analysis of the mutational rate
in cancer genomes, investigation of the growth promoting effect and transformation in
cell lines, xenograft models with cells with the altered gene, modification of the gene in
in vivo organisms, etc. This deregulation leads to uncontrolled growth and eventually
metastasis – a state where cells detach from the main tumor and circulate to a new
location (Fig. 1.1 and 1.2).
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Tumor Suppressors Tumor Growth Metastasis
Oncogenes
Figure 1.2: Tumor Suppressors and Oncogenes. Tumor Suppressors fail to inhibit
growth and metastasis while oncogenes promote it.
Cells have evolved several mechanisms to preserve and tightly regulate the cell state in
order to restrain uncontrolled growth. Therefore, initial attributes cancer cells acquire
are alterations in pathways that sustain their living state as well as promoting growth.
One of these attributes is the ability to resist cell death whereby the cell builds up
the potential of constant proliferation without activating pathways that lead to self-
destruction (i.e. apoptosis). One of the main players in activating apoptosis is a tumor
suppressor gene known as the guardian of the genome, TP53 (Lane, 1992; Vousden and
Prives, 2009). TP53 is a transcription factor and is known to activate apoptosis by
several mechanisms, such as activation of Apaf-1 (a coactivator of caspase-9) (Kannan
et al., 2001), upregulation of expression of caspase-6 (MacLachlan and El-Deiry, 2002),
or activation through cytochrome C release (Schuler et al., 2000), all which lead to the
activation of the caspase cascade. Caspases have cysteine protease activity that cleaves
targeted proteins and plays a core role in the apoptosis pathway (Fridman and Lowe,
2003).
Furthermore, TP53 in addition to its ability to lead the cells to apoptosis is responsible
for cell cycle arrest in response to damage as well as senescence and therefore considered
as a growth suppressor. For example, in DNA damaged cells, TP53 gets activated in
order to enable the cells to repair their genome before continuing the cell cycle. This
allows mutations that would potentially activate oncogenes to get repaired, before passing
the damaged genome onto daughter cells. If the DNA damage is severe, the cells might
be driven to senescence, a state where the cell cycle arrests irreversibly.
Additional functions of TP53 are its association with metabolism, autophagy and stem
cell biology, which also play important roles in tumorigenesis (Bieging et al., 2014).
4
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Previous studies have shown that complete dysfunction of TP53 leads to 100% pene-
trance in tumor formation in mice (Donehower et al., 1992). However, TP53 is not always
inactivated, but some tumors harbor point mutations in domains that disrupt TP53 par-
tially which can then be advantageous for the tumor (Zhu et al., 2015a). Analysis of
several tumor types have shown to have TP53 mutated with a penetrance up to 80%,
such as in breast basel carcinoma (Hoadley et al., 2014). Lastly, the whole TP53 path-
way is found to be the most commonly affected pathway across cancers (Stracquadanio
et al., 2016). In summary, TP53 is involved in several pathways that sustain the cell
state, control growth and cell death and therefore is considered to be a major tumor
suppressor gene (Bieging et al., 2014; Cosme-Blanco et al., 2007; Liu et al., 2004).
Apart from tumor suppressors that are responsible for activating apoptosis or restraining
growth, oncogenes also play an important role in tumorigenesis. Oncogenes can be clas-
sified in six groups: transcription factors, chromatin remodelers, growth factors, growth
factor receptors, signal transducers and apoptosis regulators (Croce, 2008). The first
example of an oncogene was the the constitutive activation of the SRC gene (Stehelin
et al., 1977). SRC was discovered through the formation of tumors by the Rous sar-
coma virus in chickens (Stehelin et al., 1977). SRC plays an important role for signal
transduction in many pathways affecting proliferation, differentiation, cell adhesion and
migration (Parsons and Parsons, 2004). Oncogenic SRC harbors mutations that result
in a constitutively active SRC protein. Hence, the cell receives constant growth signaling
through oncogenic SRC resulting in tumorigenesis.
Another important factor in sustaining growth is replicative immortality. Generally,
cells have a limited number of divisions due to telomere shortening. Telomeres are
repetitive sequences in the end of each chromosome to protect them from fusion and
shortening. When telomeres become too short, cells are driven to senescence or to crisis
(d’Adda di Fagagna et al., 2003; Hayashi et al., 2015; Maciejowski et al., 2015). In cancer
though, cells achieve a state of immortalization with infinite divisions, which is linked to
telomere restoration (Blasco, 2005). The main gene responsible for telomere lengthening
is telomerase and it is overexpressed in approximately 90% of cancers (Hanahan and
Weinberg, 2011; Kim et al., 1994). The remaining cancers have activated alternative
lengthening pathways of telomeres termed ALT (Alternative Lengthening of Telomers)
(Henson et al., 2002).
5
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Besides its role in cancer evolution, telomerase immortalization has thoroughly been
used in establishing cell lines in order to achieve unlimited proliferative potential. These
immortalized cell lines can be used to investigate hypotheses of cancer development and
are therefore of high importance.
1.1.2 Cancer epistasis
Tumor genomes typically evolve by combinations of genomic alterations rather than
changes acting on single genes. MYC and mutant RAS both known oncogenes, were the
first example to demonstrate such synergistic effect. Whereas overexpression of either
MYC or RAS was unable to generate tumors, the combination of both oncogenes was
able to generate fast growing tumors in mice, indicating their cooperative actions (Land
et al., 1983). Since then, such interactions have been found to be quite common in
cancer, contrary to initial expectations (Wang et al., 2014b).
This type of gene interaction (GI) is known as epistasis and describes the situation where
a resulting phenotype of a gene is dependent on another gene (Park and Lehner, 2015).
There, the observed phenotype of these GIs is not additive (i.e. adding the effect of both
genes) but can be in some cases synergistic, for example in proliferation (Fig. 1.3). Genes
that express proteins involved in same pathways are considered to have masking effects
since the outcome of alterations of either or both genes results in the same phenotype
(Wang et al., 2014b). Masking effects were found to be more common than epistatic
effects when investigating mutated cancer genes in breast cancer, indicating that mutated
genes are frequently involved in the same pathways (Wang et al., 2014b).
Only combination 
which gives rise to
uncontrolled growth
Single nucleotide variant
Structural variant:
          Deletion
 Duplication
 Inversion
 Translocation
Figure 1.3: Epistasis resulting in proliferation.
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As described, epistasis plays an important role in cell growth. Epistatic effects can also be
exploited to inhibit growth. An analogous concept to epistasis in treating cancers is that
of synthetic lethality. Synthetic lethality describes when the inhibition of two genes in
combination lead to cell death while the individual inhibition of either does not, or has a
weaker effect. Knockdown screens have shown that RAS oncogenic mutant tumors have
a synthetic lethal effect in combination with inhibition of the APC/C (the anaphase
promoting complex), among several other candidates (Luo et al., 2009). Therefore,
synthetic lethality is an attractive approach for tumor treatment (Astsaturov et al.,
2010; Kaelin, 2005; Luo et al., 2009).
Furthermore, data mining projects have attempted to investigate the co-occurrence of
tumor suppressors and oncogenes in tumors. Several identified combinations of tumor
suppressors and oncogenes were linked and simultaneously mutated in tumors (Zack
et al., 2013; Zhu et al., 2015b).
A good example of a GI that highlights the importance of epistasis in cancer was iden-
tified between Brac1 and Trp53 (Xu et al., 2001). Mutant Brca1 in mice (exon 11
deficient mutant) could not give rise to viable mice due to activation of apoptosis. By
depleting Trp53, mice were viable rescuing the Brca1 deleterious phenotype. This GI
has importance for tumorigenesis since Brca1 repairs double strand breaks in the chro-
mosomes and Trp53 activates apoptosis, resulting in a deficient combination that favors
tumor cell evolution.
Epistasis therefore has an important effect in tumors and studying modification of cells
in different genetic backgrounds can shed light in previously unidentified GIs. Under-
standing the forces that enable the cells to overcome the initial barriers for tumorigenic
growth is therefore essential to understand cancer initiation and develop further thera-
peutic strategies. For this reason, one of my aims was to identify GIs of tumor suppressors
of initial driver events that result in uncontrolled cell growth.
1.1.3 Genomic alterations
Genomic alterations in the form of PMs and SVs are important hallmarks that can
enhance tumor evolution by effecting gene expression. PMs and SVs could be either
acquired gradually, as the classical cancer model describes (Cavenee and White, 1995),
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or in bursts, where multiple alterations could happen under one event (Nik-Zainal et al.,
2012; Stephens et al., 2011). These two different routes may compliment each other, for
instance with gradual mutation accumulation being punctuated by periodic mutational
bursts (Yates and Campbell, 2012) (Fig. 1.4).
Figure 1.4: Gradual and crisis tumor evolution. Cancer genomes can evolve gradually
or in bursts. Interplay between these two routs could also influence cancer evolution.
Figure adapted from Yates and Campbell (2012).
PMs, alterations of a single bases, can lead to activation of proto-oncogenes or inacti-
vation of tumor suppressors. Constitutive activation of oncogenes has been observed in
many cancers such as a point mutation in KRAS (McCoy et al., 1984) that results to
altered amino acid leading to its activation or point mutations in EGFR (Lynch et al.,
2004) resulting in alterations in the ATP-binding pocket of the tyrosine kinase domain,
both of which result in stimulation of growth in the same pathway. In contrary to
oncogene activation, PMs can inactivate tumor suppressors by introducing a stop codon
within the coding sequence, such as in RB, a major G1 checkpoint gene, leading to the
production of truncated, non-functional protein (Horowitz et al., 1989). Furthermore,
instead of PMs affecting genes, they may also influence activation of genes by alter-
ing promoter sequences, allowing new transcription factors to bind, for example seen in
melanomas with the TERT promoter (Huang et al., 2013).
In contrary to PMs, larger rearrangements, structural variations (SVs) can result in alter-
ations of several genes at once. SVs can occur as deletions duplications/amplifications,
inversions and translocations (Weischenfeldt et al., 2013; Zhang and Pellman, 2015).
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Deletions involve a loss in genetic material and may be as large as whole chromosome
or focal and can contain tumor suppressors (Yin and Shen, 2008). Duplications and
amplifications provide the cell with additional copies of a genomic locus or whole chro-
mosomes, which could give rise to numerous copies of oncogenes (Albertson, 2006; Saliba
et al., 2015). Inversions can switch the orientation of genes. Although they do not alter
the dosage of genetic material they can modify the chromosome structure, leading to
changes in regulatory landscapes (e.g. enhancer positioning) which may lead to changes
in gene expression (Roberts et al., 2002). Translocations also result in shuﬄing material
of different chromosomes and are linked to cancer by causing instability (Mitelman et al.,
2007; Stankiewicz and Lupski, 2002). Complex karyotypes containing many SVs have
been associated with poor prognosis in cancer (Zack et al., 2013). Additionally, several
SVs have shown to be recurrent even across cancers indicating common driving forces
for the evolution of some cancer types (Zack et al., 2013).
SVs can also result in gene fusions, whereby an oncogene may be overexpressed due to
the stitching of its loci to a non-tumorigenic, but highly expressed, gene. These chimeric
genes have been shown to be responsible for the outcome of several cancers making gene
fusion a common mechanism of oncogene activation (Mertens et al., 2015; Yoshihara
et al., 2015).
Shuﬄing of the genome has not only shown to cause direct alterations on the genes but
also in the genomic neighborhood affecting enhancers. Enhancers are genomic sequences
that employ transcription factors to activate the expression of a nearby gene. Clustered
enhancers in a region are commonly referred as super-enhancers and are considered to
drive strong gene expression (Hnisz et al., 2013). Therefore SVs can shuﬄe enhancers
to new targets, which can activate proto-oncogenes (Gröschel et al., 2014). This has
been thoroughly investigated for group III type medulloblastoma for the activation of
the GFI1 gene through different types of rearrangements (duplications, inversions and
deletions) (Northcott et al., 2014). The investigation of SVs of the non-coding genome
and deciphering their mechanism of action was one of the focuses of this thesis.
Independently of the path tumors take to evolve, each cell in the tumor population
acquires its own set of mutations, which results in heterogeneity within the population.
Beneficial mutations can lead to clonal expansions that may outgrow the rest of the cells
under different conditions or stresses. Genomic instability enhances heterogeneity and
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can serve as an indicator of the potency and aggressiveness of the tumor and also of its
drug resistance. Hence, heterogeneity, a result of many mutational processes, is crucial
for tumor growth and also a great burden for cancer treatment (Fisher et al., 2013).
1.2 Genetic Engineering
Due to advances in technology, especially in the last decade, genetic engineering has
become a vital procedure in research. Genetic engineering is a process of precisely mod-
ifying the genome of an organism in order to alter properties of the cell or the organism.
Main uses involve loss of function and gain of function experiments, which result in com-
plete loss or modification of gene expression in cells. Another application is gene tagging,
which can be utilized for protein localization and trafficking experiments, flow cytome-
try and cell sorting experiments as well as chromatin immunoprecipitation (Dominguez
et al., 2016).
One of the first model organisms that genome engineering was thoroughly applied to was
budding yeast, due to their efficient homologous recombination (HR) repair mechanism
which allowed for efficient integration of foreign genetic material (Orr-Weaver et al.,
1981). Since then yeast genetics have become a very powerful system to study gene
function. Until recently, establishing an efficient system in other organisms had been
very challenging. Tools that played an immense role in genetic engineering are restriction
enzymes also called "molecular scissors", which introduce breaks in the DNA in precise
locations. The cell will repair the breaks by mechanisms such as non-homologous end
joining (NHEJ) and HR (Sancar et al., 2004). Repair by NHEJ can result in alteration
of the DNA sequence and produce a frame-shift in a coding region. HR is a more precise
repair mechanism and by using a repair template can lead to a specific genomic edit.
1.2.1 Programmable nucleases
The use of nucleases greatly increases the efficiency for genetic engineering. However,
common restriction enzymes cut the genome too frequently, which makes them imprac-
tical for genetic editing. Therefore, nucleases that cut the genome with high specificity
are the preferred enzymes to alter the genome. One of the first class of nucleases used for
10
Chapter 1. Introduction
this purpose were meganucleases, which recognize a large sequence in the genome and in-
troduce a double strand break (Epinat et al., 2003). Later, by editing the sequence of the
meganucleases, they could be programmed to target different sites (Epinat et al., 2003).
Despite the potential of meganucleases precise editing was very challenging. The further
investigation of new classes of engineered nucleases, zinc-finger nucleases (ZNFs) and
transcription activator-like effector nucleases (TALENs), enhanced the field of genetic
engineering.
ZNFs make use of fusing a zinc-finger DNA binding domain to a non-specific nuclease
domain of the FOKI restriction enzyme (Kim et al., 1996). Zinc-finger proteins utilize
zinc to fold the protein and have been identified to bind DNA, RNA, proteins, etc.
(Gamsjaeger et al., 2007). ZNFs can be engineered and used in tandem to recognize and
break specific DNA sequences (Urnov et al., 2010). Therefore ZNFs can be directed to
specific sites in the genome (Fig. 1.5a).
TALENs are another class of DNA binding proteins, which similar to ZNFs, are fused
with FOKI nuclease. Transcription activator-like effectors (TALEs) are proteins secreted
by a bacteria species called Xanthomonas. TALEs contain highly variable sequences
and are shown to bind strongly to specific nucleotide sequences. The variable sequence
they carry is termed repeat variable di-residues (RVDs) which can bind specifically to
certain nucleotides (Boch et al., 2009) and hence can be programmable to target specific
sequences. Therefore TALENs can easily direct the nuclease domain to specific sequences
in the genome and introduce a break (Fig. 1.5b).
A promising successor in the genetic engineering field after the programmable TALENs
is a nuclease found in bacteria named Cas9, which is a core component of the bacterial
adaptive immune system Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR) (Fig. 1.5c).
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Figure 1.5: Programmable nucleases. (a) Genome targeting by zinc-finger nucleases
(ZNFs). Zinc-finger domains recognize a set of three DNA bases. When the whole Zinc-
finger array recognizes its target the attached FOKI nucleases can introduce breaks
on the DNA. (b) Genome targeting by transcription activator-like effector nucleases
(TALENs). Each domain in the TALEN recognizes a specific base according to the
repeat variable di-residues (RVDs) domain. Similary when the whole array is attached
to the DNA target the FOKI nucleases introduce breaks on the DNA. (c) Genome
targeting by CRISPR/Cas9 nuclease. A gRNA guides the Cas9 nuclease to a targeted
site. Firstly, the Cas9 recognizes a protospacer adjacent motif (PAM) with sequence of
“NGG” and then if the gRNA is compliment to the adjacent DNA sequence, the Cas9
introduces a double strand break.
1.2.2 CRISPR/Cas9 based genetic engineering
CRISPR is a defense system found in multiple bacteria species (Doudna and Charpentier,
2014; Wright et al., 2016). The CRISPR locus is defined by palindrome repeats sepa-
rated by short sequences called protospacers (Fig. 1.5c). The transcribed protospacer
sequences coupled with CRISPR associated proteins (Cas) bind uniquely to a targeted
DNA sequence, which is then cleaved by the nuclease domain of the Cas protein. The
protospacer sequence is integrated by specialized Cas proteins, inserting pieces from the
foreign DNA into the genome (Barrangou et al., 2007; Datsenko et al., 2012; Nuñez et al.,
2015). The repeats and protospacer sequence are transcribed and matured and guide the
nuclease Cas protein to cut foreign DNA. By this means, bacteria can acquires adaptive
immunity to the foreign DNA, particularly that of invading bacteriophages. Although
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the bacteria host transcribes the protospacer sequences, the Cas proteins do not target
the bacteria’s genome, due to the absence of the protospacer adjacent motif (PAM). PAM
is a short sequence found adjacent to the target site of the protospacer motif. The Cas
protein firstly recognizes the PAM sequence and then the protospacer sequence attempts
to anneal at the targeted locus. A cut is only introduced if the protospacer anneals
perfectly. Therefore PAMs are essential for the CRISPR system since they provide an
elegant system to distinguish between the bacteria genome and the invading species.
The CRISPR bacteria immune system is classified into five types (Makarova et al., 2015)
and all work under the same principle; a nuclease guided by a transcribed RNA (Bar-
rangou, 2015). The most popular and well studied system is the type II CRISPR/Cas9
isolated from Streptococcus pyogenes. It consists of three basic components: the CRISPR
associated protein 9 (Cas9), the CRISPR RNA (crRNA) and the trans-activating crRNA
(trRNA). The Cas9 binds to a crRNA-trRNA complex and is guided to a targeted site.
The Cas9 protein recognizes the PAM sequence of “NGG” and only in those sites it will
attempt to anneal the crRNA (Fig. 1.5c). After the correct hybridization of the guide
RNA duplex, the Cas9 protein creates a double strand break three bases upstream of
the PAM sequence. The Cas9 nuclease domains are RuvC and HNH (Tsai and Joung,
2016) and each creates a nick in the opposite strand.
Advances in the CRISPR/Cas9 system involve the construction of a fused crRNA and
trRNA which is called guide RNA (gRNA) (Jinek et al., 2012). This chimeric RNA
molecule abolishes the need of a trRNA co-transcribed with the crRNA, constituting a
highly efficient molecule to guide the Cas9 nuclease to a targeted site (Jinek et al., 2012).
After the break occurs, the cell signals DNA repair pathways to stich back the cut DNA.
In mammalian cells the DNA may then be repaired using the error prone NHEJ repair
mechanism (Tsai and Joung, 2016). If the DNA is correctly repaired, the active Cas9
can bind again and introduce another cut. Therefore, Cas9 stops cleaving only when
the repair pathways introduce errors at the break site, altering the targeted sequence.
These errors can include deletions or insertions of a single or multiple base pairs. If the
alteration is in a coding region and not in frame with the rest of the coding sequence,
the transcript will be translated to a non-functional protein (Fig. 1.6).
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Figure 1.6: Erroneous repair. CRISPR/Cas9 targets a specific locus guided by the
gRNA and introduces breaks to each DNA strand. Then the repair machinery will repair
the break. If the repair is inaccurate, a frame-shift may occur that when translated it
will produce a functioning protein.
1.2.3 Further applications in genetic engineering
With the advances in programmable nucleases, genetic engineering has become a routine
task in laboratories. One of the main applications is the construction of gene knockout
libraries as previously described. Using this approach, large sets of guides can be syn-
thesized and cloned in parallel, creating a pool of guides that can target up to all genes
in the human genome (Shalem et al., 2014; Wang et al., 2014a).
Another advance is fusion of genes to fluorophores resulting in tagged proteins. By
cutting at the first or last codon of the gene, fluorescent markers can be inserted with a
repair template. The repair template consists of homologous sequences to the adjacent
locus. Mediated by HR, the cell can insert the repair template in a precise manner and
create a gene fusion (Stewart-Ornstein and Lahav, 2016).
Furthermore, combinations of guides can be used to create structural rearrangements in
the genome. They can be used to create deletions in exons of genes, or remove large
genomic loci. It has also been shown that introducing two guides to cut two adjacent
sequences can create a variety of rearrangements, including deletions, duplications, am-
plifications and inversions (Kraft et al., 2015).
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Moreover, gene expression can be regulated by activation or repression according to the
protein fused to DNA binding domain of the nuclease. Such DNA binding domain and
regulatory domain fusions were initially created with zinc-finger proteins or TALEs (Gers-
bach and Perez-Pinera, 2014). Since Cas9 proved to be a simple straightforward system,
by eliminating the nuclease domains with point mutations, the dead-Cas9 (dCas9) is
converted to a DNA binding molecule (Gilbert et al., 2013, 2014; Perez-Pinera et al.,
2013). The dCas9 can then be fused to activator proteins resulting in overexpression of
genes, or repressor proteins, which can result in controlled reduction of gene expression
without perturbing the gene sequence.
Lastly, dCas9 can be tagged with fluorophores and targeted loci can be visualized in
living cells (Chen et al., 2013), showing an alternative method to fluorescent in vitro
hybridization (FISH). In addition to this note, different Cas genes have been identified
to target RNA and therefore live RNA-like FISH experiments.
In conclusion CRISPR systems have revolutionized the field of genetic engineering. Ele-
gantly designed older strategies are combined with a simple programmable system that
can readily, precisely and in high throughput manner edit almost any loci in the genome.
It is expected that many more advances will occur in the next years utilizing CRISPR.
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Chapter 2
Recapitulating Genomic
Rearrangements of IRS4 and IGF2
Implicated in Enhancer Hijacking
This chapter describes the efforts of recapitulating enhancer hijacking related rearrange-
ments of IGF2 and IRS4 identified in tumor genomes. Furthermore, the driver role of
IRS4 in tumorigenesis is investigated and supported using mouse xenografts. The re-
sults described in this chapter are partly included in the recently submitted manuscript
entitled:
Pan-cancer analysis implicates IRS4 and IGF2 in enhancer hijacking
JoachimWeischenfeldt*, Taronish Dubash*,Alexandros P. Drainas*, Balca R. Mardin,
Yuanyuan Chen, Adrian M. Stütz, Sebastian M. Waszak, Graziella Bosco, Ann Rita
Halvorsen, Benjamin Raeder, Theocharis Efthymiopoulos, Serap Erkek, Christine Siegl,
Hermann Brenner, Odd Terje Brustugun, Sebastian M. Dieter, Paul A. Northcott, Iver
Petersen, Stefan M. Pfister, Martin Schneider, Steinar K. Solberg, Erik Thunissen, Wilko
Weichert, Thomas Zichner, Roman Thomas, Martin Peifer, Aslaug Helland, Claudia R.
Ball, Martin Jechlinger, Rocio Sotillo, Hanno Glimm#, & Jan O. Korbel#
* Equally contributed to the project; # Joint senior authors
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Contributions
Jan Korbel, JoachimWeischenfeldt and I conceptualized and designed the work presented
in this chapter. I designed all used vectors with the support of Balca Mardin and Adrian
Stütz. Furthermore, with the help of Joachim Weischenfeldt I designed the screening
strategy, which I then conducted together with Adrian Stütz and Benjamin Raeder. I
and Benjamin Raeder carried out the majority of the cell culture work with occasional
help of Adrian Stütz and Theocharis Efthymiopoulos. The qPCR experiments were
conducted by Adrian Stütz. Library preparation for sequencing was performed by Adrian
Stütz and Benjamin Raeder. I contributed to the design of the mouse xenograft project
in collaboration with Yuanyuan Chen, Adrian Stütz, Joachim Weischenfeldt, Martin
Jechlinger, Rocio Sotillo and Jan Korbel. I mainly designed the vectors used in the mouse
project with support of Adrian Stütz and Joachim Weischenfeldt. All mouse related
work was performed by Yuanyuan Chen and I contributed by conducting downstream
experiments on the mouse tumors, interpretation and analysis of results. For the related
paper I played a key role in the development of figures. Jan Korbel guided and supervised
the project providing valuable and insightful feedback.
2.1 Introduction and Motivation
Up to date, structural variations (SVs) and point mutations (PMs) of the genome have
been extensively studied in protein-coding regions. SVs and PMs have shown to promote
tumorigenesis in several ways. For example, PMs causing missense or frame-shift alter-
ations can result in hyperactivation of oncogenes or inactivation of tumor suppressors.
Larger SVs, such as deletions or amplifications, can remove tumor suppressors or am-
plify oncogenes respectively. However, only 1% of the genome is translated to proteins,
whereas the rest is composed of cis-regulatory elements (Roadmap Epigenomics Consor-
tium et al., 2015; Zhu et al., 2013). Cis-regulatory elements can act from a distance up
to several megabases and affect gene expression.
Although the non-coding genome seems to be more tolerant to mutations and somatic
variants, recent studies suggested that SVs and PMs could influence the non-coding
genome and promote tumorigenesis (Horn et al., 2013; Northcott et al., 2014; Peifer et al.,
2015). Such mechanisms may result in generating new binding sites for transcription
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factors resulting in increased expression of oncogenes or disruption of transcription factor
binding sites at tumor suppressors (Ludlow et al., 1996; Mansour et al., 2014). Recent
examples in medulloblastoma, neuroblastoma and leukemia have shown SVs to juxtapose
an enhancer to an oncogene, which can result in high upregulation of the respective gene
(Hnisz et al., 2016; Northcott et al., 2014; Peifer et al., 2015). This phenomenon has
been described as enhancer hijacking (EHJ) (Northcott et al., 2014).
Recently we described the extent of EHJ in a systematic pan-cancer study of 7,423
tumor genomes from 26 tumor types and have shown several genes to be affected by
EHJ (Weischenfeldt, Dubash, Drainas et al. in revision), suggesting EHJ an important,
alternative and frequent mechanism of tumorigenesis.
We employed an approach which applies the statistical concepts of expression quantita-
tive trait locus (eQTLs) and somatic copy number alterations (SCNAs – non-balanced
SVs, such as deletions, duplications and amplifications) to identify SCNAs that lead
to deregulation of gene expression in cis (Fig. 2.1). The principal lies in partitioning
the genome based on topological associated domains (TADs) and investigating within
these TADs the association between SCNAs and gene expression. TADs are large (esti-
mated average size 1Mb) chromatin interacting units that have high levels of chromatin
associations in comparison to the rest of the genome and are thought to help mediate
control of gene regulation (e.g. enhancer-promoter interactions) within the 3D structure
of TADs (Dixon et al., 2012). TADs can be identified based on Hi-C experiments – a
technique that can capture physically interacting chromatin in 3D space (Dixon et al.,
2012; Pombo and Dillon, 2015). Comparison and association of SCNAs and TADs was
applied for each cancer individually as well as across multiple cancers (pan-cancer). The
SCNAs were defined based on SNP6 arrays, which are DNA microarrays that can identify
single nucleotide polymorphisms (http://cancergenome.nih.gov/).
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Figure 2.1: The principle behind the approach used for identification of SCNAs associ-
ated with overexpression of genes in close proximity is depicted. Topological associated
domains (TADs) are shown from Hi-C contact maps (a technique that identifies long
range interactions). The darker shading indicates stronger interaction. The search
space of the method used is according to TAD size. After a rearrangement a non-
cognate enhancer can be relocated next to a gene and drive its high expression. Figure
was adapted from Weischenfeldt, Dubash, Drainas et al. (in revision).
2.1.1 Colorectal cancer analysis implicates IGF2 in enhancer hijacking
Among the different tumor types analyzed, we identified colorectal as the most affected
tumor type of potential EHJ events. The top candidate was IGF2 which was associated
with a cluster of SCNAs that led to its upregulation. IGF2 belongs to the insulin family
of growth factors. IGF2 is involved in development and growth but was also suggested
to act as an oncogene in cancer when misregulated (Brouwer-Visser and Huang, 2015;
Cui et al., 2003).
Specifically, we identified a cluster of duplications encompassing IGF2 which was asso-
ciated with high upregulation (up to 1000 fold) of IGF2 (Fig. 2.2). The high levels
of IGF2 overexpression exceeded the amount that would be overexpressed by a dosage
model. A dosage model would only result to an overexpression of 1.5 fold (since the
genome will have three copies instead of two), which is much lower than the identified
IGF2 levels observed, suggesting an alternative model of activation. Apart from dupli-
cations, deletions were also identified in close proximity to IGF2 that led to its high
upregulation (deletions depicted in Fig. 2.7).
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Figure 2.2: IGF2 enhancer hijacking. (a) Active chromatin marks, H3K27Ac (Ernst
et al., 2011), show signals at the IGF2 locus in the samples that carry the duplication but
not in the controls. Next, 4C-Seq experiments indicate a physical interaction between
IGF2 and the super-enhancer in samples that carry the duplication but not in the
controls. The opposite, using the super-enhancer as viewpoint verifies the specific
physical interaction with IGF2 in the samples that carry the duplication. (b) The
boxplots show the relationship between expression and SCNAs for all genes within the
respective TAD. IGF2 has the highest expression in the samples with the recurrent
SCNAs in cis but not in the control samples lacking SCNAs. The boxplots depict
deletion (DEL), duplication (DUP) and amplification carriers (AMP; >4 copies) as
well as controls. Figure is adapted from Weischenfeldt, Dubash, Drainas et al. (in
revision).
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In order to further study the mechanism of how the SCNAs result into IGF2 overexpres-
sion, we screened colorectal spheroid cell lines to identify cells that carried high IGF2
overexpression. Spheroids are cell lines kept in 3D cultures and in comparison to normal
(2D) cultures are considered to be more similar to actual tumors, making them more
appropriate models for studying tumorigenesis. DNA sequencing of two spheroid lines
with high upregulation of IGF2 revealed that they carried the same duplication found in
the colorectal tumors. Then the H3K27Ac status was tested, which can be evaluated as
a marker for active chromatin and is tested by chromatin immunoprecipitation followed
by high-throughput sequencing (ChIP-seq) (Ernst et al., 2011). H3K27Ac marks on the
gene were present in the samples that carried the duplication but not in the non-carriers.
Afterwards, 4C-seq (van de Werken et al., 2012), a method to identify long range genomic
interactions in 3D, indicated a physical connection of IGF2 to a nearby super-enhancer,
which can explain the increased expression levels of IGF2. The experiment identifies
physical connections of a targeted genomic region (called the viewpoint) to any other
locations in the genome. This experiment was conducted from the viewpoints of the
gene and of the super-enhancer and both indicated an interaction between the gene and
the super-enhancer (Fig. 2.2a) but not to its known cognate enhancer (Leighton et al.,
1995). None of the other genes in the vicinity of IGF2 showed a high overexpression
(Fig. 2.2b), indicating in this case the super-enhancer interacts presumably only with
IGF2 and drives its expression.
Hence, the duplication coupled with high overexpression suggests that IGF2 is activated
by enhancer hijacking rather than by gene dosage in which the latter would result in
only 1.5 increase of expression (Fig. 2.3).
IGF2 cognate enhancer
IGF2
Super-enhancer
Recurrenty tandemly 
duplicated segment
De novo
chromatin domain
Distal
TAD
WT
IGF2-TAD
Distal
TAD
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IGF2-TAD
Figure 2.3: IGF2 enhancer hijacking mechanism of activation. The proposed model
depicts the formation of a new contact domain that brings in close proximity IGF2
and the super-enhancer from the adjacent TAD. Figure is adapted from Weischenfeldt,
Dubash, Drainas et al. (in revision).
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2.1.2 Pan-cancer analysis implicates IRS4 in enhancer hijacking
We further analyzed all available cancer genomes simultaneously (pan-cancer) in order
to identify genes activated by enhancer hijacking across cancers. With this approach, we
identified the insulin receptor substrate 4 (IRS4 ) as the major candidate. IRS4 can be
phosphorylated by the insulin tyrosine kinase receptor and when phosphorylated, IRS4
plays a role in growth and proliferation as well as in insulin metabolism (Qu et al., 1999).
Clustered deletions in proximity to IRS4 associated them with high expression of IRS4.
Even more pronounced were the clustered deletions found specifically to lung squamous
carcinoma (Fig. 2.4). The clustered deletions cross a TAD and result in up to 2000
times upregulation of IRS4 (Fig. 2.4). SCNAs across multiple cancers are shown as
a heatmap, further supporting that these clustered deletions match the most common
deleted region (Fig. 2.4).
Lung tumors were screened for IRS4 upregulation and then sequenced for the presence of
the deletions. Cells positive for the SCNA and overexpression of IRS4 were investigated
further. Firstly, the H3K27Ac marks status were tested, and were present in the samples
that carried the deletion but not in the non-carriers. Then we investigated whether IRS4
is connected to a cis regulator element in close proximity. In both IRS4 overexpressing
samples and controls, IRS4 was connected to transcription factor binding sites found in
close proximity to IRS4 (Fig. 2.4). We hypothesize that the TAD boundary or a loss
of an insulator ensued to spreading of active chromatin. In the context of an already
established promoter-enhancer interaction the active chromatin can result in activation
of IRS4 (Fig. 2.5, Weischenfeldt, Dubash, Drainas et al., in revision).
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Figure 2.4: Recurrent SCNAs in cis are associated with IRS4 expression increase.
(a) Recurrent deletions at a TAD boundary near IRS4 and amplifications in the locus,
are associated with IRS4 upregulation in lung squamous cell carcinoma. The figure
depicts as heatmaps summarized SCNAs across cancer types (pan-cancer copy-number
gains and losses). The deletion carriers have elevated H3K27Ac marks at a region near
IRS4, which is absent in the controls. Transcription factor (TF) binding sites (candi-
date cis regulatory element) are highlighted with an arrow. Samples (S00086, S00473,
SCCP38T, SCCP17T) that carried an SCNA exhibited higher expression using semi-
quantitative RT-PCR and qPCR (Weischenfeldt, Dubash, Drainas et al., in revision).
Lastly, 4C-Seq experiments using the candidate cis regulatory elements as a viewpoint
in deletion carriers versus non-carrier control samples are depicted. DEL, deletion;
DUP, duplication; WT, wild-type locus. (b) Expression measurements in LUSC (unad-
justed RSEM gene expression values) for deletion carriers versus controls, reveal IRS4
as the most overexpressed gene in the locus. Figure is adapted from Weischenfeldt,
Dubash, Drainas et al. (in revision).
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Figure 2.5: Proposed model for IRS4 overexpression. The clustered deletions result
in loss of the TAD boundary in cis and allow active chromatin spreading and activation
of IRS4. Figure is adapted from Weischenfeldt, Dubash, Drainas et al. (in revision)
IRS4 has not been characterized as an oncogene yet. The presented analysis suggests
it as a potential new oncogene in cancer. This finding gives reason to screen for IRS4
overexpression in tumors (particularly in lung tumors) and potential therapeutics could
be explored for treatment.
Motivated from the above results, we sought to recapitulate the genomic alterations
that resulted in enhancer hijacking in cell lines. Using CRISPR/Cas9 technology, we
attempted to re-engineer alterations associated to IGF2 expression in colorectal cancer
cell lines, as well as IRS4 in lung cancer cell lines. As described in the introduction (see
section 1.2.3), a combination of gRNAs can be used to generate a variety of rearrange-
ments. We therefore used gRNAs in combination with or without templates to achieve
the specific rearrangements.
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2.2 Results
The strategies chosen to perform the genetic engineering are shown in Figure 2.6. In
order to perform the deletions, I designed gRNAs that introduce breaks at the genomic
coordinates of rearrangements found in tumors. To select a specific rearrangement, a
donor template construct was provided with a selection marker (Fig. 2.6a and Table
5.2). Cells were then selected and enriched using flow cytometry. In order to perform
the duplication, a similar strategy was designed using a template in an orientation that
if homologous recombination occurs between separate chromosomes, it can result in a
duplication (Fig. 2.6b). The strategy for the duplication was based on a similar approach
applied in yeast (Huber et al., 2014). In order to screen cells that obtained the vector
expressing the gRNAs and Cas9 as well as the template vector, selection markers were
used. After selection I tested with PCR whether the rearrangements were present in the
population of cells (see Appendix Fig. A.1). Then, single cells were sorted with FACS
in order to obtain individual cell clones. After the cells were confluent in the sorted
plates, they were collected from all wells and subpools of approximately twelve clones
were generated. From these subpools, DNA was extracted and each rearrangement was
tested again by PCR. The individual clones in these subpools that gave the expected PCR
product were then individually grown to larger wells and DNA was extracted from each of
the clones. Clones with the desired rearrangement were further tested by qPCR in order
to asses the overexpression levels of the gene of interest (IGF2 or IRS4 ). Additionally,
whole genome sequencing was performed to verify whether the rearrangement was indeed
present and also to identify any other possible secondary rearrangements that might have
occurred (Fig. 2.6c). The screen was applied to IGF2 and IRS4, which were the most
promising candidates that were identified from the tumor specific and pan-cancer analysis
for enhancer hijacking (Weischenfeldt, Dubash, Drainas et al. in revision). An overview
of the screen is depicted in Appendix (Fig. A.2).
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Figure 2.6: Screening strategy to generate rearrangements. (a) Targeted deletion
generation strategy using a template to drive homologous recombination through the
homologous arms (HA). Selection is based on GFP intensity and shorting with FACS.
((b) Targeted duplication generation strategy using a template to drive homologous re-
combination through the HAs. Selection is based on neomycin resistance. ((c) Screen-
ing strategy to identify cells that harbor the engineered rearrangements. First cells
are transfected or transduced with the designed gRNS that target for the rearrange-
ment. Then selection takes place to enriched for the cells that obtained the gRNAs.
Next, a PCR reaction is performed to test whether the rearrangement is present in the
population of cells. If successful, single clones are sorted. Subscreening with PCR of
smaller pools accelerates the screening process. Finally single clones are screened for
the presence of the rearrangement and qPCR as well as whole genome sequencing is
performed.
2.2.1 Generation of IGF2 enhancer hijacking associated rearrange-
ments
First, we sought to recreate a duplication event for the cluster of duplications found in
colorectal cancer (Fig. 2.2) as well as for the deletions (Fig. 2.7), which all led to IGF2
overexpression. Although the deletions were not clustered, we considered recreating
deletions a more achievable task in comparison to duplications, which structurally are
more complicated. To achieve these rearrangements I used the HTC116 colorectal cancer
cell line (ATCC) as the model cell line. HTC116 was chosen due to its simplicity in
culture as well as to its effectiveness in transfection of foreign DNA.
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Figure 2.7: Selected rearrangements in the IGF2 locus. A set of deletions and a
duplication were selected according to the SCNAs identified in colorectal cancers (from
the cancer genome atlas TCGA data) that led to high IGF2 overexpression.
We applied the screening strategy depicted in Figure 2.6 to identify clones that resulted
in the selected rearrangements (Fig. 2.7). A summary of the results is shown in Table
2.1. Performing the PCR-based assays as described in the previous section, I obtained
clones for four out of the six rearrangements (Table 2.1). For these we observed an over-
expression with qPCR in two clones (Fig. 2.8ab). Since the duplication event showed
the most promising results, I screened more clones carrying potential duplicated regions
in comparison to the deletions (Table 2.1).
Table 2.1: IGF2 genetic engineering results summary. Plates from all conditions
were screened. PCR verified clones were obtained from conditions DelC, DelD, DelF
and Dup. From those, only two duplication cases showed higher expression levels by
qPCR. MP-seq was performed on the qPCR positive clones but the expected duplication
was not observed.
HTC116
Rearrangement Wells Clones Construct PCR Verif. qPCR Verif. WGS Verif.
DelA (1.6Mb) 192 7 yes 0 0 NA
DelB (510kb) 192 2 yes 0 0 NA
DelC (20kb) 384 24 yes & no 12 0 NA
DelD (7.2Mb) 384 24 yes 1 0 NA
DelF (CTCF) 192 12 yes & no 7 0 NA
Dup (220kb) 768 65 yes 10 2 0
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Figure 2.8: qPCR and sequencing results for clones that were verified by PCR to
harbor a duplication event. (a) qPCR was performed on duplication positive as well on
negative WT clones (qPCR Figure and experiment performed by Dr. Adrian Stütz).
(b) Summary of data. The clones with higher overexpression are highlighted in yellow.
The clone with the expected fold change is highlighted in blue. (c) Read depth plot of
MP-seq of clone with highest IGF2 overexpression. Chromosome 11 is depicted. IGF2
locus carries a duplication signature and is also highly amplified. Zoom in of 0-5 Mb
region is displayed (sequencing libraries prepared by Dr. Adrian Stütz and Benjamin
Raeder).
We further examined the clones with the highest overexpression with Sanger sequencing
(Materials and Methods 5.3.7) and verified that the clones indeed carried a duplication
rearrangement. Additionally, we performed long-range paired end (mate pair) sequencing
(MP-seq) to fully characterize the rearrangements we observed in the qPCR (Materials
and Methods 5.1.6). Such an approach can give a detailed representation of structural
rearrangements. Only one out of the two clones showed a duplication signature in which
a sharp increase in the read depth was observed, indicative for a high level amplification
of the affected locus (Fig. 2.8c). The degree of overexpression (52 times) can be explained
by the degree of amplification, which is approximately 44 times higher. Therefore, this
overexpression clone was due to high-level amplification rather than EHJ. From these
results no EHJ event was detected. PCR verification of the rest of the clones (also by
verified by Sanger sequencing) indicates that the rearrangement may have been achieved,
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but only the qPCR positive clones (the ones with higher IGF2 expression) were tested
by MP-seq.
2.2.2 Generation of IRS4 enhancer hijacking associated rearrange-
ments
Considering the EHJ analysis across tumors and specifically in lung squamous carcinoma,
I sought to recreate the deletions associated with IRS4 overexpression. Since the deletion
cluster was more prominent in lung squamous cancer, I used the following lung squamous
cancer cell lines to model the deletions: HCC15, H520 and H2170 (Table 5.1). From these
H520 and H2170 gave few clones and could not be scanned in all conditions. Recreation
of six deletions (DELs) were tested as depicted in Figure 2.9. Genomic coordinates of
Del-A and Del-C were selected according to inner and outer coordinates of the deletion
cluster, whereas Del-B was selected as a separate deletion. The remaining three deletions
were chosen according to actual deletion coordinates in the lung tumors that had the
highest expression of IRS4. For the first three (Del-A, Del-B and Del-C) two gRNAs were
used to introduce breaks in each coordinate to increase efficiency, whereas for the next
three (Del-1, Del-2 and Del-3) only one gRNA per site was used based on the cutting
efficiency (Materials and Methods 5.3.8).
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Figure 2.9: Selected rearrangements in the IRS4 locus. A set of deletions were
selected according to the clustered SCNAs identified in lung cancers (from the cancer
genome atlas TCGA data) that were associated with high IRS4 overexpression. Del-A
was selected according the to the outer coordinates of the clustered deletions, Del-C
was selected according to the inner coordinates of the clustered deletions, Del-B as a
deletion outside the clustered deletions. Del-1,2,3 were selected according to actual
deletion coordinates from the TCGA data with the highest expression levels.
30
Chapter 2. Recapitulating Genomic Rearrangements of IRS4 and IGF2 Implicated in
Enhancer Hijacking
The screening strategy was applied as described in Figure 2.6 with a modification. In-
stead of transfection, virus transduction was used (Materials and Methods 5.1.4). All
deletions selected were initially verified in the population of cells by PCR. From the
screening method single clones were identified and verified by PCR, which carried the
deletion. A summary of screening results is depicted in Table 2.2.
Table 2.2: Summary of IRS4 screening results. All clones obtained were tested by
PCR for the presence of the rearrangement. PCR positive clones were further Sanger
sequencing, whole genome sequenced and also tested for IRS4 expression levels with
qPCR. Positive results are indicated in the Table. NA: non-applicable
HCC15/H520
Rearrangement Total wells Clones PCR Sanger WGS qPCR
Del-A (323kb) 192/192 16/19 0/1 NA NA 0/0
Del-B (175kb) 192/192 18/29 2/0 2/NA 2/NA 0/0
Del-C (5kb) 192/192 21/19 1/0 1/NA not clear 0/0
HCC15/H2170
Del-1 (200kb) 384/384* 192/192 5/17 5/NA 1/NA 0/0
Del-2 (121kb) 384/192 192/38 8/1 8/NA 0/NA 0/0
Del-3 (105kb) 768/384 384/76 1/NA NA NA 0/NA
*more than one cell sorted in wells in order to increase screening depth
None of the generated clones exhibited overexpression of IRS4. In order to verify that the
deletions were indeed generated, two approaches were undertaken. The first approach
was to verify the junction of the rearrangement with Sanger sequencing. For the sec-
ond approach low-coverage whole genome sequencing was applied (LC-WGS) in order
to identify the deletion based on the read depth information (Materials and Methods
5.1.7). From the first approach 36 positive clones were identified, indicating that such a
rearrangement is present in the clones. Two samples of Del-B were verified by MP-seq
and the rest were tested with LC-WGS. From the LC-WGS results we were identified
one sample that carried the deletion (Fig. 2.10). Though, the absence of the deletion in
the sequencing data but present in the Sanger sequencing data, may suggest that the re-
arrangement had occurred but the piece was not lost from the cell, but rather integrated
somewhere else in the genome. Therefore we tested all Sanger sequenced positive cases
with qPCR. From the 16 cases tested we were unable to identify any IRS4 overexpressing
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clone. Although I achieved to recreate the rearrangements in a lung squamous cancer
cell line, no overexpression resulted from this rearrangement. This indicates that there
might be additional factors involved that lead to overexpression of IRS4 as seen in the
tumors.
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Figure 2.10: Read depth plot of LC-WGS of a clone positive for the deletion in
PCR. Chromosome X is depicted. IRS4 adjacent locus has a deletion at the expected
coordinates. Zoom in of 107.5-109.5 Mb region is also displayed.
2.2.3 Identification of IRS4 as a potential oncogene
IRS4 was found to be frequently overexpressed in the pan-cancer analysis and suggested
as a potential oncogene (Weischenfeldt, Dubash, Drainas et al. (in revision)). In order
to investigate its oncogenic properties in vivo, we designed mouse xenograft experiments
and studied the growth rate of tumors with and without IRS4 overexpression. To this
end, we subcutaneously injected HCC15-IRS4 and HCC15-mock cells (lung squamous
cancer cell lines) into athymic nude mice. This experiment was conducted with two
independent replicates (N=8 for each group in the first experiment, N=9 for control
and N=12 for IRS4 overexpressing sample in the second experiment).
The outline of the experiment is depicted in Figure 2.11. To obtain a verified IRS4
overexpressing transgene vector, IRS4 transgene was ordered (Origene). Then IRS4
was removed from the vector in order to have a control vector (Materials and Methods
5.2.2). Lentivirus was then prepared from each vector and the cells were infected. Next, I
performed two rounds of fluorescent activated cell sorting (FACS), to sort cells according
to their GFP intensity. By this, I obtained enriched cells that have the vector stably
integrated in their genome. Then I tested whether the protein indeed is translated to
IRS4 by immunoblotting (immunoblotting of control and IRS4 HCC15 cell lines can be
seen in Fig. 2.13c).
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Figure 2.11: Scheme of xenograft experiments in mice. IRS4 and control vector over-
expressing HCC15 cell lines were generated by lentivirus integration. Then by measur-
ing GFP intensity stable integration of the vectors was confirmed. The cloned HCC15
cell lines were then injected into mice and tumor sizes were measured after one week
every four to five days. The tumors were harvested and qPCR, FACS, immunoblotting
and immunohistochemistry were conducted.
After confirming the expression of IRS4 in the protein level we proceeded with injection
of the cells into mice (all mouse related work was kindly conducted by Dr. Yuanyuan
Chen, Deutsches Krebsforschungszentrum, Heidelberg). We observed tumor formations
in both IRS4 overexpression and control cell injections. The tumors harboring the
IRS4 overexpressing plasmid were significantly larger indicating increased tumor growth
(P=0.046 and P=0.03, respectively in last time point; two-tailed t-test; Fig. 2.12).
These experiments support the tumor promoting role of IRS4 in carcinogenesis.
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Figure 2.12: Growth experiments between IRS4 overexpressing and control
xenografts. Boxplots depicting mouse tumor progression curves of HCC15 cells contain-
ing IRS4-expressing lentiviral constructs (pLenti-IRS4) versus mock control (pLenti-
empty HCC15); 1x106 cells injected respectively; last time point: 1st P=0.046, 2nd
P=0.03; two-tailed t-test; two-tailed t-test computed at last measured time point (day
39); N=8 for each group in first experiment, N=9 for control and N=12 for IRS4
overexpressing sample in second experiment. Figure and caption text adapted from
Weischenfeldt, Dubash, Drainas et al. (in revision).
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We then tested whether resected tumors maintained IRS4 overexpression using four in-
dependent approaches. Firstly, we measured RNA expression with qPCR and showed
that in both experiments, IRS4 overexpressing cell lines indeed had higher IRS4 levels
in comparison to the controls. Secondly, FACS also indicated that a large population
of cells in each tumor was indeed GFP positive, which indicates the cells tested car-
ried the vectors. Thirdly, with immunoblotting I confirmed that five out of eight IRS4
overexpressing tumors indeed contained higher levels of IRS4 protein. Lastly, immuno-
histochemistry showed in both experiments that IRS4 protein was overexpressed in the
expected tumors (Fig. 2.13).
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Figure 2.13: (IRS4 overexpression verification experiments. a) qPCR of the control
and IRS4 overexpressing HCC15 tumors confirming IRS4 overexpression (experiment
performed by Dr. Yuanyuan Chen). (b) Flow cytometry of tumors injected with
HCC15-IRS4-GFP confirm the expression of the vector by measuring the GFP inten-
sity. (c) Immunoblotting of protein extracts of the xenografts of the first experiment,
indicating protein expression in at least seven out of the ten xenografts. (d) Immunohis-
tochemistry represents IRS4 protein expression in the HCC15-IRS4 harvested tumors
but not in the control tumors in both experimental replicates. Figure is adapted and
modified from Weischenfeldt, Dubash, Drainas et al. (in revision).
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2.3 Discussion
In the presented study we estimated potential enhancer-hijacking events across cancers
and identified potential candidates. The analysis was based on SNP6 microarrays and
associated deletions and duplications with high expression levels of nearby genes (Weis-
chenfeldt, Dubash, Drainas et al., in revision). From this analysis we investigated
further the mechanism of activation of two genes: IGF2 a top candidate in colorectal
carcinoma and IRS4 a top candidate across many different cancers, specifically in lung
squamous adenocarcinoma.
For IGF2 we identified a cluster of recurrent duplications resulting in a much higher
expression of IGF2 that cannot be explained by a gene dosage model. We could further
verify the connection of IGF2 with an enhancer from another topological associated
domain (TAD). This was verified in spheroid cell lines that harbored the duplication and
had high IGF2 expression.
IRS4 locus revealed a set of recurring deletions within the COL4A5/A6 genes, but not
in IRS4, which resulted in high IRS4 overexpression. The deletion in the COL genes
resulted in their under-expression as expected. This further implies that IRS4 is the
only candidate of the locus that is associated with high expression.
Based on these observations and results, we attempted to recreate these rearrangements
that were associated with overexpression. The cell lines selected for the experiments were
specific to each tumor type, therefore a colorectal cell line and lung cell lines were used
for IGF2 and IRS4 respectively. During my PhD thesis work was published that recre-
ated rearrangements in the genome using the CRISPR/Cas9 system (Kraft et al., 2015;
Li et al., 2015) but they did not investigate enhancer hijacking (EHJ). They showed that
genomic engineering had low efficiency, which is in line with my observations. However,
these studies did not further characterize the rearrangements by whole genome sequenc-
ing which gives another layer of detailed validation, an important step we performed that
confirms the presence of the rearrangements.
Initially, I attempted to re-engineer the rearrangements associated with IGF2 overex-
pression and selected a set of deletions and a duplication (from the duplication cluster).
Although the genomic coordinates of the deletions were not as similar to each other as
the duplications, I initially attempted to generate those since deletions are structurally
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simpler than duplications. I achieved to recreate four out of the six rearrangements
designed for IGF2 in the HCT116 cell lines (Fig. 2.7). Only for the duplication I was
able to observe a difference in expression thus proceeded to analyze these events fur-
ther. From all clones that I had tested, only one clone led to high expression of IGF2.
PCR and Sanger sequencing verified this clone to carry the duplication. To investigate
the rearrangement in detail, long range paired end sequencing (MP-seq) was used to
examine the read depth and structural rearrangements. MP-seq revealed, despite the
confirmation of a duplication, a high level amplification (Fig. 2.8). Therefore this clone
was dismissed as a putative enhancer hijacking event since the level of overexpression
could be explained by the amplification. Unfortunately the remaining clones that I had
similarly analyzed did not exhibit overexpression of IGF2.
For IRS4, I attempted to engineer the deletions according to the cluster of deletion
found in lung cell carcinoma (as well as in the pan-cancer screen). We designed different
approaches for selecting the deletions and for introducing the breaks. The first three
were designed according to inner and outer coordinates of the deletion cluster in order
to capture the whole range of the deletion as well as the minimal region. With this we
reasoned that we would have more insight on the region that results in EHJ. Also we
designed guides that target a deletion outside the clustered rearrangements, which also
resulted in overexpression of IRS4. For these rearrangements I applied two gRNAs per
coordinate, to assure that a break will occur. For the next three, deletion coordinates
were selected based on the events observed in the tumor, to assure that we recreate
actual deletions observed. Furthermore, one gRNA per side was designed and tested
with an assay that measures break efficiency. One gRNA was used in order to minimize
the amount of off target effects that each gRNA might introduce to the genome, for
example from having two from each side. We screened over 3500 wells and identified 36
clones according to PCR verification. We achieved to recreate all deletions according
to the Sanger sequencing data. For further validation we confirmed with whole genome
sequencing that only three cases have the deletion (two with MP-seq data and one with
LP-WGS). The confirmation rate with the LP-WGS was very low in comparison to
the PCR and Sanger sequencing verification. LP-WGS though is not able to identify the
orientation and position of the sequenced data, which might explain the low confirmation
rate. The reads are aligned to a reference therefore only read depth information is
obtained but not an actual position. Therefore if the piece is not lost from the cell, we
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will not see any drop in the read depth in the expected position. The PCR and Sanger
sequencing data suggest that that the rearrangement did occur, however the piece was
not lost from the cell but presumably integrated somewhere else in the genome. In order
to verify this hypothesis, two approaches can be used, MP-seq on the clones tested only
by low coverage sequencing or fluorescent in vitro hybridization (a technique that can
visualize DNA with a targeted probe).
Unfortunately, by recreating the respective SV events in the cell lines, we did not observe
any IRS4 overexpression as hypothesized from the pan-cancer analysis data. Although
we verified three clones (two harboring the deletions out of the cluster and one within)
with all techniques, no IRS4 overexpression was observed. Moreover no IRS4 overex-
pression was observed in any of the other clones verified by PCR and Sanger sequencing.
Multiple parameters may influence why we did not observe gene overexpression from
enhancer hijacking. All cell lines used in culture are grown in optimal conditions and
overexpression of these genes may have no benefit for the cells in culture. Another reason
may be that the targeted enhancers are not active in the cells in culture. Therefore the
resulting rearrangement will then not give any increase in expression. Moreover the
chromosomal state in the cell lines is different to tumors, as observed in previous studies
for measuring epigenetic H3K27Ac marks and DNA methylation, which influence open
and active chromatin (Hovestadt et al., 2014; Lin et al., 2016). The latter parameter is
important because the structural conformation of the chromosomes, which is influenced
by the epigenome of the DNA, might provide an explanation to why we did not to see
enhancer hijacking in this context.
In conclusion, targeted rearrangements were obtained and verified by PCR and Sanger
sequencing but no overexpression of IGF2 nor IRS4 was observed. Experiments in vivo
may be more relevant to actual tumors, since the correct cell types can be targeted with
the natural chromosomal state and may result in the observed enhancer hijacking events
that lead to gene overexpression.
Next, we investigated the tumorigenic role of IRS4. To achieve this we investigated the
tumor growth in mice xenografts. I generated cell lines that stably overexpressed IRS4 or
a control vector, by lentivirus infection. The cells were subcutaneously injected in mice
and tumor growth was measured regularly. Although individual mice exhibited different
rates of tumor growth, overall we concluded from two independent experiments that the
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IRS4 overexpression significantly increased tumor growth. All tumors were also tested
for IRS4 overexpression with various techniques (Fig. 2.13). Therefore these results
indicate that IRS4 plays an oncogenic role in promoting tumor growth.
2.4 Conclusions
Enhancer hijacking was observed more commonly as previously thought in cancer as
indicated from the pan-cancer analysis described in the introduction. To recapitulate
such events is not trivial since it is likely an effect resulting from the combination of
multiple parameters, including cellular context or possibly modifiers not yet understood.
Although we were unable to detect EHJ in the cell lines tested, we were able to recreate
the majority of the selected rearrangements found in tumors, indicating the functionality
of genomic engineering in the cell types tested.
As observed from the pan-cancer analysis, some candidates were found across several
cancers but others were cancer specific. This could be due to gene specificity in the
different tumors. Furthermore the microenvironment and the chromosomal state of the
cell might have a large influence in enhancer hijacking. Therefore, investigating in in vivo
models may greatly enhance the possibility of targeting a cell with optimal chromosomal
state that will lead to enhancer hijacking.
Lastly, we investigated the tumorigenic role of IRS4 in in vivo models. We used lung
squamous cell lines overexpressing IRS4 and performed xenograft experiments in mice.
The tumors observed from the overexpression IRS4 group in comparison to the control, in
two individual experiments, gave significantly larger tumors. This points to a tumorigenic
role of IRS4 and hence may be an important target to investigate for cancer therapy of
IRS4 overexpressing tumors.
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Chapter 3
Identification of Drivers of Growth
as Potential Tumor Suppressor
Genes via Genome Wide
CRISPR/Cas9 Knockout Screens
This chapter describes genome wide knockout screens for the identification of genes
that drive cell growth and may be potential tumor suppressors. The screens led to the
development of ScrispR, a tool to analyze the data. As a result, genes related to the Hippo
and the mTOR pathways were mostly enriched. Novel candidates of promoting growth,
AHR and FRYL were further investigated and combined with the outcome of additional
analysis of the cancer genome atlas are suggested as potential tumor suppressors.
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Contributions
This chapter contains mainly my own work with support of others along the development
of the project. I conceptualized the work of this chapter together with Balca Mardin
and Jan Korbel. I designed and led all experiments related to the screens. Furthermore,
I conducted the initial library preparations, which were then optimized by Adrian Stütz
and Benjamin Raeder. Sebastian Wazsak proposed the main concept of the ScrispR tool.
I then led the development and application of the tool. The final package was written
and optimized by Mike Smith. I conducted the analyses of all screens receiving valuable
input and advice from Balca Mardin and Sebastian Wazsak. I supervised the analy-
sis performed by Ruxandra Lambuta relating the ubiquitination pathway. Moreover, I
established the crystal violet assay and its analysis with help from Benjamin Raeder
and Ruxandra Lambuta. Also, I conducted the downstream analysis for the AHR and
FRYL genes. I developed the method to identify knockout clones by interpreting com-
plex Sanger sequencing information. Adrian Stütz and Benjamin Raeder prepared the
libraries for sequencing. The TCGA analysis, which helped me further support the re-
sults of the screens, was kindly conducted by Christopher Buccitelli. Balca Mardin and
Jan Korbel guided and supervised the project and provided valuable and insightful feed-
back. From the work regarding this chapter a manuscript will be written where I will be
the first author.
Publication related to this chapter:
A cell-based model system links chromothripsis with hyperploidy
Mardin B. R., Drainas A. P., Waszak S. M., Weischenfeldt J., Isokane M., Stütz A.
M., Raeder B., Efthymiopoulos T., Buccitelli C., Segura-Wang M., Northcott P., Pfister
S., Lichter P., Ellenberg J., Korbel J.O.
Molecular systems biology, 11(9) 828–828, 2015.
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3.1 Introduction and Motivation
In order to model neoplastic growth in vitro, reconstructing the important steps in cancer
genome evolution is essential. Previous studies aimed at identifying contributors to
tumor growth in different cell types at different stages, using either shRNA based screens
(Silva et al., 2008) (downregulation) or CRISPR/Cas9 screens (Shalem et al., 2014)
(complete knockout). These screens not only identified known tumor suppressors such as
PTEN, but also revealed novel candidates, such as REST (Westbrook et al., 2005), JNK
pathway associated genes (Eskiocak et al., 2011) or genes important for tumor invasion
and metastasis such as XPO4 (Zender et al., 2008), ADAMTS18 (Ly et al., 2012), GAS1
(Gobeil et al., 2008), SALL1 (Wolf et al., 2014), NF2, PTEN and CDKN2A (Chen et al.,
2015).
Until recently, screens that identified novel tumor suppressors have only employed shRNA
libraries. However with shRNA based libraries complete inactivation of a gene is not
possible as opposed to knockouts e.g. achieved by CRISPR/Cas9 system. Furthermore,
screens that studied essential genes showed that CRISPR/Cas9 based screens outper-
formed shRNA screens in effectiveness, false positives and off target effects (Evers et al.,
2016). This can be due to various reasons, one of which is low expression of genes being
sufficient to reduce or prevent a phenotype. In order to study the complete loss-of-
function of a gene, CRISPR/Cas9 based libraries have been constructed and employed.
Moreover, up to date, a systematic whole genome knockout screen to identify genes
involved in tumor initiation has not been performed. Previous screens did not target
the whole genome, but a smaller set of genes. Lastly, as mentioned in the introduction
(see section 1.1.2), genetic interactions (GIs) play an important role in tumorigenesis
and several tumor associated genes have shown to interact genetically, indicating that
epistasis in cancer is a frequent event (Wang et al., 2014b). A detailed investigation of the
epistatic interactions and their importance to tumor initiation has not been performed
yet.
In order to study epistatic interactions I made use of isogenic cell lines in my CRISPR/-
Cas9 based screens, which already contain certain hallmarks of tumor evolution such
as replicative immortality (e.g. hTERT activation), resistance to cell death (TP53 in-
activation) and hyperploidy (as a result of induced genomic instability) (Table 3.1).
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Despite having these attributes, the cells are mostly unable to grow unattached to a
surface; thus they are considered as non-transformed (and therefore can be considered
non-tumorigenic), but have shown to be capable of transformation (Mardin et al., 2015).
I used isogenic cells lines with TP53 deficiency and hyperploidy since these backgrounds
have shown to increase cancer risk substantially (Mardin et al., 2015). This encouraged
us to test for genes with potential tumor suppressor activity in these genetic backgrounds.
To understand the mechanisms of transformation I used a powerful tumorigenic predictor:
anchorage-independent growth (ANIG). ANIG is utilized in a soft agar assay, where
transformed cells are able to grow in an agarose matrix (Fig. 3.1). Over the past
few decades ANIG on soft agar has been used as a marker for in vitro transformation
(Mori et al., 2009). It also has been reported to be associated with tumorigenicity and
metastatic potential in vivo (Freedman and Shin, 1974).
Non-transformed
epithelial cells 
Transformed
Soft agar assay
Non-transformed
Figure 3.1: Soft agar assay. Transformed epithelial cells are able to grow in soft
agar in comparison to non-transformed cells. HeLa cells and RPE-C7 are transformed
cells whereas RPE-1WT and RPE-1TP53
-/-
are unable to grow and thus considered non-
transformed.
ANIG was previously employed in our laboratory leading to the development of a method
termed CAST (Complex Alterations after Selection and Transformation) (Mardin et al.,
2015). CAST is based on applying perturbations on cell lines (chemical or genetic) and
afterwards subjecting them on soft agar to test for ANIG. Cells that grow in soft agar,
which are considered to be transformed, are then pooled in batches and subjected to
low-pass massively parallel whole genome sequencing. Applying CAST we were able to
identify several transformed clones some of which carried complex rearrangements con-
sistent with patterns of chromothripsis (Mardin et al., 2015). In addition, we were able
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to demonstrate that a chemical or genetic perturbation can be sufficient to induce trans-
formation, showing the robustness and efficiency of the assay. We then reasoned that
combining genome-wide knockout screens (Hart et al., 2015; Shalem et al., 2014; Wang
et al., 2014a) (see Section 1.2.2) with a powerful tumorigenic assay, such as CAST, can
have the potential to lead to the discovery of genes that contribute to cell transformation
representing potentially tumor suppressors.
Table 3.1: RPE and MCF10A isogenic cell lines used in study.
Cell line Information Reference
RPEWT Retina pigment epithelial cells ATCC
RPETP53-/- RPE with disfunctional TP53 Mardin et al. (2015)
RPETP53-/-,hyperploid RPETP53-/- with whole genome duplicated Mardin et al. (2015)
MCF10A Mammary epithelial cells ATCC
MCF10ATP53-/- MCF10A with disfunctional TP53 Custom Generated
Previous screens have used similar methods to ANIG, combining them with shRNA li-
braries that target several genes (Westbrook et al., 2005). CRISPR/Cas9 screens have
the advantage of complete destruction of the gene rather than diminishing their expres-
sion in comparison to RNAi based libraries (i.e. siRNA or shRNA). siRNA screens have
to be performed in multi-well format and therefore make large scale screens very labori-
ous. shRNA screens can be performed in bulk, however since down-regulation of the gene
is not complete, minimal expression of the gene might be sufficient for the function of
the gene, thus can mask the relevant phenotypes. Therefore CRISPR/Cas9 screens offer
a superior alternative to the RNAi based screens and have shown to be quite effective
(Hart et al., 2015; Shalem et al., 2014; Wang et al., 2014a).
For our experiments I employed the GeCKO (Genome-wide CRISPR/Cas9 Knockout)
library screening approach (Shalem et al., 2014). The GeCKO library was designed to
target the majority of genes in the human genome. Initially the authors obtained a list of
genes with the most common transcripts expressed across several cell types. The strategy
was to design gRNAs that target the first exons of each gene, and a set of six gRNAs
per gene were designed. The gRNAs were planned to have minimal off target effects
in the genome (Hsu et al., 2013). In addition, GeCKO library targets 1,864 miRNAs,
introducing potentially interesting targets in non-gene elements. Furthermore GeCKO
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also encompasses 1000 control gRNAs (gRNAs without any matches in the genome) and
therefore can be used as a negative control for the phenotype of interest. In total 123,411
gRNAs were designed (Fig. 3.2). Since the set of gRNAs was considered to be too large
for a single library, the library was divided to two subsets: Libraries A and B. Each
library contains three guides per gene and also the same 1000 control guides. Library A
contains additionally the gRNAs that are designed to target miRNAs.
Cloning 
gRNA oligo 
libray into 
lentiviral 
constructs
3 gRNAs per 
gene per 
library
Oligo array 
synthesis
sgRNA oligo library design
GeCKO library A &
GeCKO library B
Transduction with 
GeCKO library
Analysis of the remaining 
sgRNA pool
Six gRNAs per gene
19,050 genes
1,864 miRNAs
1000 controls
Figure 3.2: GeCKO library design. Initially most common transcripts were identified
and gRNAs were designed to target the first exons, in total six gRNAs per gene. The
gRNA sequences were synthesized using oligo array synthesis technology. The oligos
were cloned into a lentiviral backbone and viral particles are constructed. The cells
are transduced with the virus and are subsequently selected for antibiotic resistance.
The surviving cells are processed for the screen of interest. Image and strategy adapted
from Sanjana et al. (2014) and Shalem et al. (2014).
The designed library was acquired from Addgene as a pooled library. The strategy of
the screen has three main steps: first library amplification, second virus packaging and
last transduction and selection. In the end of the selection, analysis of the remaining
gRNA representation indicates which gene knockouts resulted in the phenotype of interest
(Sanjana et al., 2014; Shalem et al., 2014)(Fig. 3.2).
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3.2 Results
3.2.1 Methodological overview
The strategy of the screen is depicted in Figure 3.3. Initially lentivirus was prepared to
infect the non-transformed cell lines in all cell lines in replicate (Materials and Methods
5.3.1.1, Table 3.1). Lentiviruses have the ability to integrate their genome into the
host genome even in non-replicating cells. This gives the system the ability for stable
integration of genes of interest, which for the GeCKO library are Cas9, gRNA and a
puromycin resistance gene used for selection. Therefore, puromycin selection enriches
cells that incorporated the viral DNA. In order to assure transduction of ideally one
gRNA per cell, I conducted a titration experiment to estimate the multiplicity of infection
(MOI) and a low MOI was selected (Material and Methods 5.3.1.2).
Following antibiotic selection, a portion of the cells was collected. This serves as a
baseline of the representation of gRNA sequences before soft agar selection (indicated
as “I”, Fig. 3.3). The remaining cells were embedded in soft agar for the duration of
one month. During this time, only the cells that acquire a knockout that mediates their
growth in soft agar divide and form colonies. After one month in culture the cells were
collected. These post soft agar cells contain the final representation of gRNA sequences
(indicated as “II”, Fig. 3.3).
DNA was extracted from the bulk population of cells “I” and “II”. As depicted in Figure
3.4 libraries were prepared separately for each sample. Then, a two-step nested PCR
amplification was carried out. The first PCR amplification step is specific, in order to
ensure accurate amplification of the integrated DNA in the cell’s genome. The second
PCR amplifies the gRNA sequence while adding the necessary barcode and adaptor
sequences. After sequencing, the comparison of the representation of gRNAs before
(“I”) and after (“II”) soft agar indicated the differential representation of gRNAs (and
subsequently their respective genes) between the two populations (Fig. 3.4).
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Figure 3.3: Scheme of the transformation screen. 100 million cells are transduced
with the GeCKO virus library. The transduced cells are then selected for puromycin
resistance. After selection, a sample of cells (approximately 1/3) is collected in order to
have the initial gRNA representation in the cell population. The cells are then cultured
in soft agar. Transformed cells grow in soft agar forming clumps in comparison to non-
transformed cells. After one month the cells are collected in bulk as the final gRNA
representation. For the analysis of the screen, the transformation assay is considered a
fixed effect whereas the gRNAs and the infection of the cells are considered as random
effects.
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Figure 3.4: Library preparation. Nested PCR amplification strategy for CRISPR/-
Cas9 vector (LentiCRISPRv2) and sequencing. First, the gRNA sequence is amplified
with specific primers and then a more targeted amplification attaches the barcodes.
The amplicons are then subjected to sequencing. Analysis of representation of gRNAs
prior (“I”) and post (“II”) soft agar indicates the differentially represented genes.
3.2.2 Analysis
The data produced from each screen consist of two replicates. Each replicate contains
GeCKO library “A” and “B”. Each library encompasses three gRNAs per gene and
therefore in total both libraries contain six guides per gene (Fig. 3.2). Multiple gRNAs
are designed in order to account for gRNA efficiency as well as potential off target effects.
The gRNAs have been designed to have minimal off targets, but nevertheless off target
effects still occur (Tsai et al., 2015). Hence, having multiple guides for the same gene,
serves as a biological control. Therefore, if the majority of gRNAs targeting the same
gene give a similar phenotype, the gene that is targeted by these gRNAs is considered
as a likely true candidate.
Statistical approaches have therefore been designed to take into account gRNA variabil-
ity. These approaches were adapted from shRNA libraries, which are known to have
technical and biological variability (Hu and Luo, 2012). In such libraries, each gene is
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investigated separately and ranked in a list according to their differential representation
of shRNAs in the population. Afterwards statistical approaches assess whether there is
a bias of gRNA clustering in the ranked list and they calculate an enrichment and signif-
icance score based on a permutation test (König et al., 2007; Luo et al., 2008). Another
more recent statistical approach named MAGeCK (Model-based Analysis of Genome-
wide CRISPR/Cas9 Knockout) is designed specifically for CRISPR libraries (Li et al.,
2014b). MAGeCK uses a ranking approach and it assumes that if a gene knockout has
no effect on the phenotype, all guides will be randomly distributed in the list. On the
other hand, if there is an influence on the phenotype of interest they will be clustered.
With this rule significance of the target gene being a true hit can be derived (Li et al.,
2014b). Lastly, caRpools (Winter et al., 2015) combines the use of a variety of statistical
approaches and provides the ability to intersect the results from all tools.
Although the previous statistical approaches take guide variability by indirect methods,
they fail to take the random effect of each guide as well as the combination of differ-
ent libraries and experiments containing guides that target the same gene into account.
Therefore a statistical model that takes multiple parameters into consideration was lack-
ing.
We thus decided to develop ScrispR, a novel statistical analysis package that is designed
to take fixed effects as well as random effects of a CRISPR/Cas9 screening experiment
into account. (Materials and Methods 5.3.2). Technical effects are hereby treated as
‘random effects’ in order to account for effects that are specific to each guide. For exam-
ple, the knockout efficiency of each guide can be dependent on its “GC” content, favored
bases in the seed region, point mutations in the seed region, chromosome compaction
state, position within target gene region, etc. (Doench et al., 2014; Wang et al., 2014a).
Moreover, we have treated the GeCKO library as an additional random effect as it is
separated in two parts (A & B) and processed them independently (e.g. transduction ef-
ficiencies might vary across libraries as well as the division of gRNAs across libraries). In
contrast, the screen is considered as a fixed effect since measures only one effect: growth
or no growth in soft agar.
A scheme of the analysis is depicted in Figure 3.5. Initially, ScrispR aligns the gRNAs
to its respective reference genome. After their alignment, a count table depicting each
individual gRNA is obtained. Quality controls test whether the sequencing depth is
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sufficient and whether the data is reproducible – by using principle component and
correlation analyses. A mixed effect model (MEM) is then employed in order to account
for both fixed (e.g. before/after transformation) and random effects (e.g. gRNA) of
the screen, as described above. The MEM model assesses whether the log-transformed
abundance profile of all gRNAs per gene is different between two conditions before (“I”)
and after (“II”) transformation and accounts for quantification differences between gRNAs
and GeCKO libraries.
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Figure 3.5: Scheme of ScrispR CRISPR/Cas9 screen analysis. Initially the raw se-
quenced data is aligned to the reference, which is defined by the user. Next, quality
controls are performed in order to assess the reproducibility of the screen. Lastly, using
a MEM, ScrispR assesses the significance of a gene being overrepresented or underrep-
resented in comparison to a control population.
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3.2.3 Screen results
Selected hTERT-RPE-1 (hereafter RPE) and MCF10A cell lines were screened and an-
alyzed by ScrispR (Table 3.1 and Fig. 3.5). Initially quality controls were conducted for
each screen in order to evaluate the reproducibility and the sequencing depth (Figure
3.6 demonstrates the reproducibility of the screens in the RPETP53-/-). Next, ScrispR
tests the correlations between the two replicates. In RPETP53-/- the gRNA counts both
before and after agar selection are well correlated demonstrating the reproducibility of
the screen. The data is then normalized to sequencing depth. Principle component anal-
yses also indicate the reproducibility of the screen after normalization. Finally, density
plots of gRNA count further demonstrate the success in reproducibility and normaliza-
tion. The remaining cell lines, RPEWT and RPETP53-/-, hyperploid, had also successful
quality controls, which allowed me to proceed with the analysis (Appendix Fig. B.1).
Unfortunately, the libraries of MFC10A and MCF10ATP53-/- cell lines did not exhibit
reproducibility after agar selection, indicating technical problems during the screening
process (Appendix Fig. B.2). Since these libraries did not have sufficient quality as
assessed by the control guides, I could not use these libraries for further analyses.
ScrispR then runs a MEM on the normalized data and outputs FDR corrected P -values
for each gene (Materials and Methods 5.3.2). Plots illustrating P -values and fold changes
for each gene were generated (“Volcano plots”, Fig. 3.7).
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Figure 3.6: Quality controls of the screen. (a) The representation of each control
guide replicate was plotted against each other in order to evaluate the reproducibility
of the screen. (b) Principle component analysis plots indicate that after normalization
the replicates are similar. (c) Density plots before and after normalization. Replicates
overlap after normalization.
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Figure 3.7: Volcano plots depicting overrepresented and underrepresented genes from
each screen. Genes are highlighted according to P -value > 0.05 and fold change >
1.5. (a) RPEWT screen, (b) RPETP53
-/-
screen, (c) RPETP53
-/-,hyperploid screen. (d)
Intersection of genes from the soft agar CRISPR/Cas9 screens. PTPN14 is common
hit in all screens. NF2 and AHR are shared in the TP53 knockout and wild type
(WT) cells. PTEN, TSC1 are genes related to the mTOR pathway and were only
shared between the TP53 knockout cell lines. FRYL was also only shared in the TP53
knockout cell lines. There were no common significantly enriched genes between TP53
knockout hyperploid and the WT cells.
The plots demonstrate two populations of cells: underrepresented and overrepresented
genes. In all screens investigated, the underrepresented genes were enriched in essential
pathways, such as ribosome biogenesis, transcription, cell cycle, etc (Appendix Table
B.2). Knockouts in these pathways result to slower growth, senescence, apoptosis or
necrosis, therefore it explains the underrepresentation of these gRNAs in the population
of cells after transformation. Additionally, in the soft agar screen, genes that do not
contribute to transformation are also expected to be underrepresented. In spite of the
enrichment in essential pathways in the underrepresented gene list, essential genes cannot
be reliably evaluated using soft agar screens. Such screens have multiple parameters
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(e.g. selection), therefore assessment of essential genes can be biased by the soft agar
enrichment step.
My interest lies in the overrepresented gene lists, since they encompass enrichment of
gRNAs in response to their respective gene knockouts. In these experiments the over-
represented gRNAs likely represent contributors to cell transformation thus potential
tumor suppressors. Top overrepresented candidates were known tumor suppressor genes
(such as NF2 and PTEN ), which stresses the potential of the method to identify genes
important for the cancer development (Table 3.2).
Table 3.2: Top candidate genes that were enriched in the isogenic RPE cell lines. The
gens are sorted according to fold change and the P -values are indicated.
RPEWT RPETP53-/- RPETP53-/-,hyperploid
Gene Fold change P-value Gene Fold change P-value Gene Fold change P-value
NF2 44.0 1.00E-03 NF2 41.9 1.56E-07 PTPN14 2.7 9.18E-05
PTPN14 9.1 7.84E-06 PTEN 4.6 3.73E-04 PTEN 2.0 2.74E-02
OR2L5 3.1 1.86E-02 PTPN14 4.3 1.02E-04 TSC1 1.8 1.13E-02
PSKH1 2.8 1.92E-02 TSC2 4.0 2.86E-03 FRYL 1.6 1.65E-03
CRABP1 2.7 2.86E-02 SERPINB2 2.8 1.17E-04 FLCN 1.5 1.08E-03
CCDC11 2.7 1.28E-02 TMEM184A 2.6 6.43E-03 RNF7 1.5 2.87E-02
SHISA6 2.4 1.43E-02 PRKAA1 2.3 4.02E-02 SOWAHA 1.5 8.56E-03
TRIM33 2.4 3.66E-02 THRAP3 2.3 8.89E-03
AHR 2.4 3.03E-05 TCEAL7 2.3 9.56E-03
CPNE8 2.3 1.53E-02 FRYL 2.3 2.31E-04
PAX7 2.3 2.91E-02 TSC1 2.3 2.51E-02
CCL1 2.3 9.03E-03 GOLGA8B 2.2 6.46E-03
F8 2.3 3.69E-02 KRTAP9-2 2.2 1.63E-02
OR10A4 2.3 1.86E-02 NAPB 2.2 1.67E-03
CRISPLD1 2.2 1.77E-02 NAA30 2.2 1.58E-02
OR4X1 2.2 2.54E-02 ABCA9 2.2 4.94E-04
CFHR2 2.2 1.19E-02 C6orf222 2.1 5.89E-03
NCKIPSD 2.2 4.40E-03 SAV1 2.1 2.01E-02
MAP10 2.2 4.67E-02 PRAMEF8 2.1 1.94E-03
FZD7 2.2 2.53E-02 RSPH10B2 2.1 9.71E-03
EDC4 2.2 1.93E-02 PDCD7 2.0 5.89E-03
NOX5 2.2 2.75E-02 AHR 2.0 1.98E-03
KIRREL 2.2 3.77E-02 IL6 2.0 1.60E-02
IFNL3 2.2 8.83E-02 CAP1 2.0 2.21E-03
GRHL2 2.2 4.56E-02 DDO 2.0 9.65E-03
Protein tyrosine phosphatase, non-receptor type 14 (PTPN14 ) was the only candidate
which was significantly enriched in all screens performed in the RPE isogenic cell lines
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(Fig. 3.7). PTPN14 is a phosphatase involved in the PTP family. The PTP family
genes play important roles in several cellular processes. PTPN14 protein was shown to
assist LATS1 activation (pLATS1) that phosphorylates and inactivates YAP (pYAP –
inactive), the final target of the Hippo pathway (Wang et al., 2012; Wilson et al., 2014).
The Hippo pathway is a kinase-cascade driven signaling pathway that is conserved across
animal species. Physiologically it plays an important role in development and organ
growth as well as in stem cell function. The core proteins of the Hippo pathway are the
kinases MST1/2, which together with SAV1 activate LATS proteins. LATS1/2 phospho-
rylate YAP and TAZ that result in their nuclear export and therefore inactivate them.
Active YAP and TAZ are transported to the nucleus and result in cell proliferation and
inhibit cell death (Johnson and Halder, 2014). Tumor cells exploit this pathway by its
inactivation, and consequently suppression of growth cannot be achieved via this path-
way. Hence, in cancer it is considered as a tumor suppressor pathway and therefore its
inactivation is evident in many malignancies (Johnson and Halder, 2014).
PTPN14 has been shown to support the activation of the Hippo tumor suppressor path-
way but independently of MST1 and MST2 - core proteins of this pathway (Wilson
et al., 2016). In summary, PTPN14 acts as a tumor suppressor through activation of
YAP. Furthermore, loss-of-function mutation of PTPN14 has been identified in basal cell
carcinoma, in support of its role as a tumor suppressor (Bonilla et al., 2016).
In addition to PTPN14, other genes involved in the Hippo pathway were also enriched
such as NF2 (Hamaratoglu et al., 2006; Li et al., 2014a). NF2 was enriched in the
RPEWT as well as in the RPETP53-/- (Fig. 3.7d). NF2 was not significantly enriched
in the RPETP53-/-, hyperploid cell line, although investigation of raw counts showed two
guides indeed being enriched (Fig. B.5). Insignificance of NF2 in the hyperploid cell
line can be due to the inefficient modification of all the alleles resulting into knockouts.
Hence, one allele that is still expressing a functional protein might be enough to buffer
for the loss of the others.
Furthermore, PTEN, TSC1 and TSC2 were also enriched in the TP53 knockout cell lines
but not in the RPEWT cells. PTEN, TSC1 and TSC2 are genes involved in the Mam-
malian Target of Rapamycin (mTOR). The mTOR pathway is well known to promote
cell growth and cell cycle progression and therefore constitutively active mTOR pathway
promotes tumorigenesis (Laplante and Sabatini, 2012). The enrichment of TSC1/2 in a
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TP53 null genetic background suggests a genetic interaction between TP53 clones and
mTOR pathway genes. TP53 has been shown to inhibit the mTOR pathway in cell lines
as well as in vivo, confirming the previously suggested epistatic interactions between
TSC1/2 and TP53 (Akeno et al., 2015; Hasty et al., 2013).
Encouraged by the results confirming the functions of known tumor suppressors as well as
previously identified genetic interactions, I moved on to investigate the novel candidates
that were enriched in these screens and studied their role as potential tumor suppressors.
3.2.4 Evaluating hits
My selection was based on the investigation of genes that are not known to be involved
in transformation, uncharacterized genes and a set of known tumor suppressors. As
a positive control I selected NF2 since it was the top candidate and a known tumor
suppressor as well as PTPN14, which recently was described as a tumor suppressor in
basal cell carcinoma (Bonilla et al., 2016). For testing genetic interactions with TP53 I
selected TSC1, TSC2 and PTEN, all involved in the mTOR pathway and shown to have
epistatic effects with p53, protein of TP53 (Akeno et al., 2015). Next I selected AHR
which was shared between RPEWT and RPETP53-/- as a gene that does not show a genetic
interaction with TP53. I then selected FRYL, SERPINB2, TMEM184A, THRAP3 and
C6orf222 all of which were enriched in the RPETP53-/- but not in the RPEWT cells,
indicating potential genetic interactions with p53. Lastly, I selected RNF7 as a gene
specific for RPETP53-/-, hyperploid cell line (genes and functions are summarized in Table
3.3).
In order to assure that the genes lead to transformation, individual knockouts were
generated for each gene. Two gRNAs from the screen were selected and a third gRNA
was newly designed for each gene (Table B.4). The last gRNA was designed to assess
whether an independently designed guide has the same effect on the phenotype as the
gRNAs of the screen. After transducing each gRNA individually I subjected the cells to
soft agar (Materials and Methods 5.3.3).
In order to measure the transformation potential of each gene I set up an assay based on
crystal violet staining. Crystal violet is a dye that is able to bind to proteins and DNA,
which allows easy visualization of colonies due to its violet color (Franken et al., 2006).
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Table 3.3: Selected genes for verification and summary of their function.
Gene name Summary of gene function
PTPN14 PTP family - negative regulator of the Hippo pathway (Wang et al., 2012)
NF2 Negative regulator of the Hippo pathway (Hamaratoglu et al., 2006)
TSC1 mTOR pathway (Laplante and Sabatini, 2012)
TSC2 mTOR pathway (Laplante and Sabatini, 2012)
PTEN mTOR pathway (Laplante and Sabatini, 2012)
FRYL Furry like homolog
AHR Aryl hydrocarbon receptor – known for its biological responce to aromatic hydrocarbons (Murray et al., 2014)
SERPINB2 Plasminogen activator inhibitor-2 (Croucher et al., 2008)
TMEM184A Transmembrane protein - May activate the MAPK kinase signaling pathway (Pugh et al., 2016)
THRAP3 Involved in pre-mRNA splicing, DNA-damage response protein (Beli et al., 2012)
C6orf222 Unknown
RNF7 Interacting with PCNA, component of a E3 ligase complex (Cooper et al., 2015)
After applying the cells to soft agar I collected the transformed clones in each well and
transferred the cells back to plates so they can attach to the surface. After one week of
culturing, the amount of colonies in the plate is a direct indication of the transformation
potential of the respective knockout clone. In order to visualize the colonies I applied
crystal violet and then the plates were photographed (Materials and Methods 5.3.3, Fig.
3.8).
NF2 PTPN14 MOCKFRYL AHR
Infect cells with virus 
carring individual gRNAs
Soft agar assay Transfer to larger plates
colony growth
Colonies stained 
with crystal violet
a
b
Figure 3.8: Scheme of crystal violet screen. (a) Cells are individually treated with
the gRNAs to knockout the gene candidates. Then the cells are subjected to soft agar
and grown for one month. Afterwards each well is transferred to a larger plate, to
allow the cells to attach to the surface of the plate. Crystal violet was used to visualize
the colonies. Then each plate was photographed and the intensity of crystal violet
was measured by an in-house developed image analysis tool. (b) Raw photographs of
RPETP53
-/-
cell colonies after applying crystal violet.
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The intensity of crystal violet corresponds to the amount of colonies that grew on the
plate and can be measured. The known tumor suppressors have expectedly high signals
of crystal violet, indicating the feasibility of the method to detect cells that transformed
and grew in soft agar. On the contrary, control samples (no virus, mock virus and virus
targeting only GFP) cannot transform – and have low intensity levels from this assay
(Fig. 3.9).
All RPE isogenic cell lines were tested. From the analysis, NF2 and PTPN14 had
elevated growth indicating their high transformation potential. TSC1, TSC2 and PTEN
were mostly enriched in the RPETP53-/- cell lines but not in the RPEWT cells suggesting
the genetic interaction between mTOR proteins and p53. The remaining samples also
showed more growth comparing to the controls, but a statistical test could not be applied
since there were insufficient amounts of controls (Fig. 3.9a).
In order to examine whether the selected genes transform RPE cells specifically, I re-
peated the experiment in isogenic mammary epithelial cell lines (MCF10A). From the
selected genes I continued with three positive controls (NF2, PTPN14 and PTEN ) and
three new candidates (AHR, FRYL, SERPINB2 ). These candidates were selected due to
their transformation efficiency in the RPE cells. Each plate was manually evaluated by
the amount of colonies and colony sizes as well as their potential role in transformation.
Both AHR and SERPINB2 were suggested to increase proliferation and FRYL may have
a link to the Hippo pathway (Couzens et al., 2013; Croucher et al., 2008; Murray et al.,
2014). I performed the experiment in several replicates in order to have sufficient data
for statistical testing. A t-test was applied for a pair-wise comparison in order to investi-
gate the significance of each observation. All knockout conditions transformed the cells
significantly (Fig. 3.9b) in comparison to mock knockouts (targeting GFP) as controls.
This verified that the selected genes transformed two different epithelia cell lines and
therefore can be considered as potential tumor suppressors.
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Figure 3.9: Results from the analysis of the crystal violet screen. Three guides
per gene were grouped together. (a) Crystal violet intensities of the RPE cell lines
normalized to the intensity of the NF2 knockout clones (n=3 replicates per gRNA). (b)
Crystal violet intensities in the MCF10A isogenic cell lines normalized to the intensity
of the NF2 knockout clones (n=6 replicates per gRNA). Significance was calculated by
a t-test in comparison to the respective control group of each cell line (* < 0.05, ** <
0.01).
Using the crystal violet assay, I was able to demonstrate the transformation potential of
individual gRNAs in different cell lines. Known tumor suppressors indeed transformed
the cells and were readily detected by the assay. Negative controls showed the opposite
effect, indicating the functionality of the method. In summary, from the screen and from
these experiments I identified three genes, AHR, FRYL and SERPINB2, that have not
been previously characterized as tumor suppressors.
In the following section I focus on the investigation of the roles of AHR and FRYL in
promoting cell growth and transformation.
3.2.5 Investigation of mechanism of transformation of AHR
Aryl Hydrocarbon Receptor (AHR) is a ligand activated transcription factor that induces
transcription of several enzymes important for the metabolism of aromatic hydrocarbons
(Murray et al., 2014). AHR is also known to be involved in various cellular processes, such
as cell cycle, migration and immune function (Murray et al., 2014). Lack of AHR has been
suggested to increase tumor formation after diethylnitrosamine treatment (a chemical
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used in industry) in comparison to the wild type AHR (Fan et al., 2010). Additionally, in
a prostate tumor mouse model TRAMPAHR-/- has been reported to increase the incidence
of tumorigenesis (Fritz et al., 2007). On the other hand, constitutive activation of AHR
has also been linked to carcinogenesis (Andersson et al., 2002). In summary, there is
evidence of involvement of AHR in carcinogenesis via two different mechanisms: loss of
AHR or activation of AHR.
AHR loss-of-function might also mediate tumorigenesis through RB and β-catenin (CTNNB1 ).
AHR was shown to reduce the phosphorylation of retinoblastoma protein RB (a known
tumor suppressor), which when phosphorylated, results in the blockage of cell cycle pro-
gression (Puga et al., 2000). Additionally, AHR promotes degradation of CTNNB1, a
protein involved in the WNT signaling pathway, whose constitutive activation by muta-
tion is found in several cancers (Ohtake et al., 2009).
In order to investigate the exact function of AHR during transformation, I first gener-
ated cell lines with AHR loss-of-function alleles. Using individual gRNAs that target
AHR specifically, I isolated several clones that had potentially AHR gene disruption.
In order to verify the knockouts, I tested for loss of protein expression by immunoblot-
ting (Materials and Methods 5.1.5). Unfortunately the assay was unable to detect AHR
protein, although from mRNA sequencing data we had identified AHR expression (data
not shown). Therefore I sought to investigate the genomic locus and determine whether
the modification produces a potential knockout. I developed a method based on Sanger
DNA sequencing to identify potential knockouts (see Materials and Methods 5.3.9). This
method uses the information from the chromatogram produced by Sanger DNA sequenc-
ing, which indicates the presence of two bases instead of one clear base peak. Using
this information I was able to decipher the sequence of both alleles and therefore draw
conclusions if I have a frameshift in the coding sequence, which will result in a knockout
(Materials and Methods Fig. 5.4).
In summary with this method I was able to identify six knockout cell lines out of 13
cases. I also identified two cell lines with no allele modifications whereas five cases were
inconclusive (Table 3.4).
Then I investigated the localization of AHR by immunofluorescence (see Material and
Methods 5.3.6). I investigated two antibodies with two different cell fixation conditions.
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Both antibodies showed different subcellular localizations of AHR protein, requiring fur-
ther investigation and optimization steps (Appendix Fig. B.4).
Table 3.4: Summary of knockouts of AHR and FRYL clones in RPE cell lines
Knockouts WT N.A. Total clones
AHR 6 2 5 13
FRYL 6 2 4 12
3.2.6 Investigation of the transformation mechanism of FRYL
Another interesting candidate the screen revealed is the Furry-homolog like (FRYL) gene.
This protein shares 60% similarity to FRY, which plays a role in spindle pole integrity
during mitosis (Ikeda et al., 2012). FRYL was also identified to have a physical inter-
action with SLMAP (Couzens et al., 2013), which belongs to the striatin-interacting
phosphatase and kinase complex (STRIPAK) that regulates a variety of cellular pro-
cesses, such as cell signaling, cell cycle, apoptosis and migration (Madsen et al., 2015).
SLMAP was shown to interact with MST1/MST2 (Couzens et al., 2013), central compo-
nents of the Hippo pathway (Harvey and Tapon, 2007). Interestingly, the phosphatase
PP2A of the STRIPAK complex has already been shown to negatively regulate the Hippo
pathway, which results in cell growth (Ribeiro et al., 2010).
Similarly to AHR, in order to study the mechanisms of transformation of FRYL, I per-
formed experiments to identify knockouts. Immunoblotting experiments did not work for
FRYL protein although FRYL is expressed (data not shown). Therefore, as described
above, I used the method I developed based on Sanger DNA sequencing. With this
method, I was able to detect six knockout clones, two wild type clones and four cases
were inconclusive (Table 3.4).
Next, I sought to investigate the localization of FRYL (Materials and Methods 5.3.6).
I performed immunofluorescence with an anti-FRYL antibody. I observed FRYL to
localize in foci with a subcellular localization resembling P-bodies (Fig. 3.10). P-bodies
are mRNA processing bodies containing aggregates of riboproteins, mRNA as well as
proteins involved in RNAi. Thus they are involved in mRNA repression and decay
(Eulalio et al., 2007; Parker and Sheth, 2007).
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Next, to verify that FRYL localization is not an artifact, I tested whether FRYL knockout
clones abolishes FRYL localization. I performed immunofluorescence on all these cell
lines (Table 3.4). I observed that for four out of the six knockout cell lines there was
indeed no foci localization of FRYL. The two functional FRYL cell lines showed the
expected foci. As for the unclear cases, all of them showed a mixed signal of cells: some
with foci and some without. The latter could be due to mixed populations of cells, which
may be the reason of unsuccessful analysis with the Sanger sequencing data.
Future experiments will employ siRNAs to knock down FRYL and check the FRYL
protein localization with immunofluorescence. This experiment will show whether FRYL
indeed localizes to the P-body like foci. Additionally, in order to assure that the foci
I observed are indeed P-bodies, I will perform immunofluorescence to identify AGO2
localization. AGO2 is an important protein involved in the RNAi machinery, which is
known to localize at P-bodies (Eulalio et al., 2007; Parker and Sheth, 2007).
DNA
FRYLDNA FRYL Mircrotubules
Mircrotubules
RPETP53-/-  , Verified FRYL knockout
RPETP53-/- 
Figure 3.10: Immunofluorescence of RPETP53
-/-
stained for DNA, FRYL and micro-
tubules (alpha-tubulin). RPETP53
-/-
shows the appearance of foci in the FRYL plain
in comparison to the RPETP53
-/-
FRYL knockout cell line.
3.2.7 Structural alterations in transformed cell lines
In order to investigate the mechanisms of transformation, clones from the RPE cell lines
were picked from every condition prior testing with crystal violet. Based on previous
screens in the laboratory, a mechanism of transformation is by acquisition of somatic
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copy number alterations (SCNAs) in the genome (Mardin et al., 2015). These alterations
can alter the genome in various ways resulting in deregulation of the transcriptome and
can result in activation of pathways leading to transformation. Hence, I investigated
whether these clones acquired any SCNAs. We sequenced 69 cell lines with mass LC-
WGS (Materials and Methods 5.1.7) and investigated gross SCNAs in these clones based
on read depth analysis (Table B.1).
Analysis of all read depth plots investigated revealed that 28 out of 69 clones sequenced
had at least one alteration (Fig. 3.11). More than one alteration was observed in 14 of
the clones, of which seven of them were NF2 clones and three PTPN14. This suggests
that inactivation of the Hippo pathway may lead to increase number of SCNAs. This
could be due to the increased proliferation rate of the cells, resulting in improper repair
of potential DNA damage while continuing the cell cycle. To statistically evaluate this,
I will sequence spontaneously transformed cells as controls as well as more clones from
knockouts of tumor suppressor genes of the Hippo pathway.
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Figure 3.11: Summary of SCNAs in sequenced clones. (a) Amount of SCNAs ob-
served in RPETP53
-/-
and RPETP53
-/-,hyperploid. RPEWT did not exhibit any SCNAs.
(b) Example of sequencing read depth of RPETP53
-/-
with NF2 knockout which carries
extensive SCNAs on the q arm of chromosome 6.
3.2.8 Screen to identify potential growth suppressors
In order to understand whether the transformation is caused by growth advantage or
mechanisms specialized to anchorage independent growth, I performed screens with no
selection but growth as a constraint (Fig. 3.12). I subjected two isogenic cell lines to
the growth screen, RPETP53-/- and RPETP53-/-, hyperploid. The cells were grown for two
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weeks being split every three days. Cells were then collected and libraries were prepared
and sequenced.
Analysis using ScrispR between day 0 and day 14 was performed according to the default
settings of the program. The samples had successful quality controls, which allowed me
to proceed with the analysis (Appendix Fig. B.3). From the analysis P -values and fold
changes of each gene were calculated and then volcano plots were generated (Fig. 3.12b).
The intersection between overrepresented genes of both RPETP53-/- and RPETP53-/-,hyperploid
was further investigated. As depicted in Figure 3.12, 75 genes were commonly enriched
for both screens. Gene ontology indicated significance of several pathways including
Hippo, mTOR and ubiquitin related pathways (Appendix Table B.3). Genes involved in
the Hippo pathway are NF2, PTPN14, SAV1, LATS1, LATS2, AMOTL2 and TAOK1.
Interestingly TAOK1 knockout was highly enriched in the no-selection growth screen
but not in the transformation screen. TAOK1 is shown to activate the Hippo path-
way by activating MST1/2 (Boggiano et al., 2011; Poon et al., 2011). Furthermore
TAOK1 has shown to regulate chromosome congression and checkpoint signaling indi-
cating multiple roles of TAOK1 (Draviam et al., 2007). This suggests that inactivation
of the Hippo pathway promotes growth, as expected. Next, genes in the mTOR pathway
were enriched: PTEN, TSC2, TSC1, CAB39. Although, these genes point to the same
genetic interaction with TP53, complete evaluation is not possible since the wild type
no-selection growth screen has not been performed yet.
Interestingly, genes involved in ubiquitination and neddylation were enriched in the no-
selection growth screen. Genes important for neddylation included CUL3, CAND1,
KEAP1, as well as E2 ligases UBE2M and UBE2F. These proteins are involved in acti-
vation of cullins that eventually contribute to ubiquitin transfer to proteins and target
degradation (Petroski and Deshaies, 2005). Cullins target genes for degradation which
are involved in the cell cycle (Soucy et al., 2010; Tateishi et al., 2001). Apart from
neddylation, genes involved in ubiquitination were enriched: RNF7, KLHL21, ARIH1,
USP47, UBE2L3 and KCTD10 ). KCTD10 is an interesting candidate as it was also
highly enriched in the no-selection growth screen. KCTD10 was shown to promote the
cell cycle presumably via interaction with proliferating cell nuclear antigen (PCNA), an
important protein for replication and cell cycle progression (Wang et al., 2009). Further-
more KCTD10 was shown to interact with CUL3 (also top candidate of the screen) and
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NOTCH1 and it promotes NOTCH1 degradation (Ren et al., 2014). Notch1 pathway
has shown to be upregulated in cancer (Rizzo et al., 2008). Hence, this data suggests
that disruption of specific genes in the ubiquitination pathway lead to enhanced growth.
From the no-selection growth screen, the top candidates are indeed involved in pathways
that were suggested to promote proliferation. Interestingly most of the genes were also
enriched in the transformation screen, indicating that elevated growth itself is one of the
main contributors for transformation.
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Figure 3.12: Scheme of GeCKO screens. (a) Approximately 50 million cells were
cultured and transduced with the GeCKO virus library. Then cells were selected with
puromycin resistance for virus uptake. A sample of cells was then collected as the initial
representation. The cells were either embedded in soft agar (Fig. 3.3) or the cells were
grown for two weeks having them split every three days. Lastly, the cells were collected
for the final representation. (b) Volcano plots form no-selection growth screen. Many
top candidates are shared with the transformation screen. (c) Intersection between
RPETP53
-/-
and RPETP53
-/-, hyperploid cells.
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3.2.9 Analysis of cancer genomes for mutational occurrence of the can-
didate genes
As an initial assessment as to whether candidates reflect true tumor suppressors in clin-
ical tumors, frequencies of occurrence of point mutations in samples from The Cancer
Genome Atlas (TCGA) were compared (analysis conducted by Christopher Buccitelli).
We focused on point mutations, as their effects are gene-specific rather than large copy
number variants, which involve many genes. The tumor types most enriched for our
candidates included bladder carcinoma (BLCA), lung adenocarcinoma (LUAD), lung
squamous cell carcinoma (LUSC) and uterine corpus endometrial carcinoma (UCEC).
The most enriched gene across was the tumor suppressor PTEN as expected. Interest-
ingly next was FRYL which is also frequently mutated to approximately 8% in BLCA,
LUAD and UCEC. Combined with the growth promoting and transformation potential as
found from the screens described in the previous sections, FRYL is suggested to function
as a potential new tumor suppressor. Another interesting candidate is KEAP1, which is
related to the ubiquitination pathway. KEAP1 was commonly mutated in LUAD and
LUSC with 19% and 12% respectively. KEAP1 protein has been suggested to play a role
in cancer through regulation of NRF2 protein degradation (Hast et al., 2014; Jaramillo
and Zhang, 2013). NRF2 is important for oxidative stress and therefore cancer cells
activate this response and acquire advantages in survival and growth. Only CUL3 was
mutated up to 6.7% in LUSC but none of the other genes of the ubiquitination pathway
were as mutated as high as KEAP1.
Hippo pathway genes were under 3% mutational rate across cancers. Only PTPN14
and LATS1 had over 3% in five cancers tested with highest occurrence in UCEC (9.4%
and 4.5% respectively). NF2 though, the highest hit from the screen, was not as com-
monly mutated across cancers, a finding that came to surprise given its high growth and
transformation potential from the screens. This could be also due to investigation of
mutations and not larger SCNAs, which may lead to loss of the gene. mTOR pathway
genes, besides PTEN that also signals through mTOR, TSC1 and TSC2 had higher
mutation rates in the specific cancers tested but not across cancers.
Lastly, AHR and ARNT were mutated just over 3% in four cancers tested but none over
3% across all cancers. Further investigation as a complex as well as the mutational result
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still needs to be conducted.
In summary, mutational frequency analysis of the candidate genes show that the can-
didates are mutated and potentially relevant across many different malignancies. Some
candidates even show higher mutation frequencies than known tumor suppressors. This
result further supports the role of the candidate genes in tumor suppression.
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TSC2 4.1 0.5 1.8 1.4 1 1.2 0 4.7 2.8 0.6 6.6 1.7
TSC1 6.2 0.7 4 0.4 0.6 0.5 0 3.5 3.4 1 4.5 1.6
AHR 4.1 0.1 2.2 1.4 1 0.7 0 3.5 0.6 0.3 4.9 1.3
ARNT 1 0.4 3.1 0 1.3 0.2 0 1.7 0.6 0 2.5 0.8
KEAP1 3.1 0.3 1.8 0 4.9 0.7 0 19 12 0.6 2.9 3
CUL3 0 0.4 0.9 0 3.3 1.4 0.5 2.9 6.7 0.3 3.7 1.6
KCTD10 0 0.3 0.4 0.4 0.3 0.5 0 0 1.1 0 3.7 0.6
UBE2M 1 0 0.4 0.4 0.3 0 0 0.6 0.6 0 0 0.2
UBE2F 0 0.1 0.4 0 0 0 0 0 0 0 0.8 0.1
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Figure 3.13: Mutational frequency of selected genes in most enriched cancers as well as
across cancers (TCGA-Pancan). Mutational frequency over 3% is highlighted. BLCA,
bladder carcinoma (N=95); BRCA, breast cancer (N=742); COAD-READ, Colorec-
tal adenocarcinoma (N=85); GBM, Glioblastoma multiforme (N=138); HNSC, Head
and Neck squamous cell carcinoma (N=299); KIRC, Kidney renal clear cell carcinoma
(N=400); LAML, Acute Myeloid Leukemia (N=166); LUAD, lung adenocarcinoma
(N=167); LUSC, lung squamous cell carcinoma (N=177); OV, Ovarian serous cys-
tadenocarcinoma (N=154); UCEC, uterine corpus endometrial carcinoma (N=237);
TCGA-Pancan, all cancers (N=2660).
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3.3 Discussion
In this study, the transformation screen was designed to identify genes that can result in
anchorage independent growth when knocked out (by measuring their ability to grow in
soft agar). I hypothesized that known tumor suppressors will be among the top hits of
the assay. NF2, PTEN, TSC1 and TSC2 - all known tumor suppressors - were among
the most enriched genes, verifying the ability of the assay to identify tumor suppressors.
The assay additionally revealed candidates of cell transformation, which are potential
tumor suppressors. Two pathways were highlighted in our screen for their ability to
induce cell growth and transformation, the Hippo and mTOR pathways (Hamaratoglu
et al., 2006; Laplante and Sabatini, 2012; Li et al., 2014a).
The candidate that was shared in all screens was PTPN14. This phosphatase was shown
to activate LATS, which subsequently leads to inactivation of YAP. PTPN14 protein
activates the “executer” of the Hippo pathway, YAP, independently of the core Hippo
proteins MST1/2, indicating that the Hippo signaling cascade could be activated down-
stream of the MST1/2 kinases. Furthermore, PTPN14 inactivation has been identified
in basal cell carcinoma (Bonilla et al., 2016), revealing its tumor suppressor role.
Other components of the Hippo pathway such as NF2, were enriched in the transforma-
tion screen in both RPE and MCF10A isogenic cell lines, indicating that inactivation
of the Hippo pathway is able to transform cells. Therefore inactivation of the Hippo
pathway leads to activation of YAP through phosphorylation (Harvey and Tapon, 2007),
which results in proliferation. Despite Hippo pathway inactivation transforms cells inde-
pendently of the TP53 status, in fact it is also connected to TP53. It is evident that the
Hippo pathway inactivation is enough to promote tetraploidization of cells by inevitably
inactivating p53 (protein product of TP53 gene) – demonstrating the connection of the
Hippo pathway proteins and p53 (Ganem et al., 2014). Hence, in the RPEWT, inactiva-
tion of the Hippo pathway might work in two layers, inactivation of TP53 and promotion
of growth through YAP activation. In contrary to the TP53 knockout cell lines Hippo
inactivation promotes only growth.
In addition to the Hippo pathway, NF2, the top candidate of most screens, was also
shown to block anchorage independent growth (Bosco et al., 2010; Chiasson-MacKenzie
et al., 2015; Curto et al., 2007; Okada et al., 2005). NF2 was shown to inhibit EGFR
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in confluent cells, a receptor important for mitogenic signaling (Tomas et al., 2014).
Knockout cell lines of NF2 can result in constant signaling of EGFR which promotes
proliferation. Additionally, NF2 is shown to suppress RAC, a gene important for cell
cycle and contact inhibition (Bid et al., 2013), and sustain growth signaling in confluent
cells. Thus, despite NF2’s function in the Hippo pathway it functions in yet another
layer, anchorage independent growth.
Moreover, cell detachment or anchorage independence has also been shown to activate the
Hippo pathway (Zhao et al., 2012). Cells were found to activate the Hippo pathway when
led to anoikis – a state where the cell detaches from the colony. The exact mechanism of
Hippo activation has not been formally demonstrated, however it is tempting to speculate
that it may function through NF2, suggesting NF2 as a probable link between anchorage
independence and Hippo pathway.
In addition to the transformation screen, NF2 was found to be the most enriched gene in
the no-selection growth screen. This result indicates that growth signaling is pronounced
in NF2 knockout cells and in combination with the contact inhibition functions of NF2,
there is substantial growth also in the transformation screen.
Lastly, given that NF2 drives considerable growth through multiple pathways, acqui-
sition of structural rearrangements may be an expected outcome as described below.
The cells signal for constant growth, thus reducing the time necessary to repair any
damaged chromosomes. If the damage is not threatening for cell survival, it may get
repaired improperly and altered chromosomes can propagate to daughter cells. Addi-
tionally, SCNA acquisition was observed only in TP53 knockout clones (RPETP53-/- and
RPETP53-/-, hyperploid) but not in the RPEWT cells (Fig. 3.11). This suggests that in the
RPEWT cells, p53 gets activated upon DNA damage, which is corrected by the repair
machinery before continuing the cell cycle. Therefore, NF2 results in SCNAs but as an
indirect outcome of the cells’ ample growth, rather than playing a direct role in DNA
damage.
In summary, NF2 is shown to act on multiple pathways that all converge into accelerated
growth and consequently transformation.
Another pathway, which appeared only in the context of TP53-/- cell lines, is the mTOR
pathway. Main regulators of mTOR, TSC1 and TSC2, were both identified in the
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TP53-/- cell lines, which suggest that active p53 protein prevents transformation through
mTOR. Recent studies have shown that mTOR is highly activated upon p53 loss, result-
ing in proliferation (Akeno et al., 2015). Therefore the transformation screen was able to
identify epistatic effects between TP53 and known tumor suppressors. These genes were
also enriched in the no-selection growth screen, but to confirm the epistatic effect in this
screen, a no-selection growth screen should also be conducted in the RPEWT cells.
Novel candidates, AHR and FRYL were enriched and verified in both RPE and MCF10A
isogenic cell lines. Both have a potential influence on cell growth as described below.
Aryl Hydrocarbon Receptor (AHR) is an important transcription factor for the metabolism
of aromatic hydrocarbons (Murray et al., 2014). Thus, AHR plays an important phys-
iological role in protection of the cells of potentially toxic contaminants (Denison and
Nagy, 2003). AHR binds with the nuclear protein ARNT (Aryl Hydrocarbon Recep-
tor Nuclear Translocator) and the dimer binds highly to DNA and activates xenobiotic
responsive elements, such as CYP1A1 (Ikuta et al., 2000). Besides AHR’s response to
xenobiotic compounds (as described in the results section 3.2.5) it is also involved in var-
ious cellular processes (Murray et al., 2014; Puga et al., 2009). There is indication that
AHR is involved in cell cycle progression and apoptosis although the exact mechanisms
are unknown (Puga et al., 2009). Some may include reduction of Rb phosphorylation
by AHR (Puga et al., 2000) or degradation of CTNNB1 (Ohtake et al., 2009), both will
result in progression of the cell cycle.
Studies disrupting a ligand binding domain resulted in a constitutive active AHR, where
it induced numerous stomach tumors in mice (Andersson et al., 2002). On the other
hand, AHR-/- deficient mice also showed an increased incident of tumors in prostate
model mouse lines (Fritz et al., 2007).
In the present study I further support the view that AHR functions as a tumor suppres-
sor with two lines of evidence. First, AHR was enriched and verified in the soft agar
transformation screen in the RPEWT and in the RPETP53-/- cell lines, indicating that
AHR could act independently of TP53. Second, AHR as well as nuclear transporter pro-
tein ARNT, were both enriched in the no selection growth screen, providing additional
evidence that destruction of either protein of the dimer complex has an effect in cell
growth. Based on these findings I hypothesize that AHR acts on several pathways that
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converge on enhanced cell proliferation. Experimental testing of simultaneous activa-
tion/inactivation of these pathways need to be performed in order to identify the tumor
suppressor function of AHR.
Another interesting candidate that was enriched in both screens (transformation and
no-selection growth screen) was the Furry-homolog-like (FRYL) gene. This gene has
not been previously characterized and the protein shares approximately 60% homology
to FRY, a protein important for spindle pole integrity in mitosis. Based on their sim-
ilarity one can hypothesize that FRYL protein might also play a role in mitosis. This
may explain the genomic losses RPETP53-/- and FRYL knockouts carried indicating de-
fects in the genome of these cell lines. SCNAs were only present in RPETP53-/- cells
but not in the RPETP53-/-, hyperploid cell lines, although FRYL was also enriched in the
RPETP53-/-, hyperploid transformation screen. This could be due to the low efficiency of
knockouts in the cell line with extra chromosomes, and I did not detect any actual knock-
outs in the hyperploid cells. Additionally in the wild type RPE cells, having functional
p53 protein is a constraint for allowing rearrangements to occur, similarly to NF2 as
discussed before.
Investigating the role of FRYL in mitosis, for example with live cell imaging, can reveal
a possible connection of this protein to cell cycle machinery.
Apart from mitosis, FRYL immunofluorescence showed localization of FRYL protein
potentially in P-bodies in the wild type RPE cells but not in the RPETP53-/- verified
clones. P-bodies are important for mRNA decay and therefore might play a role in
affecting cell growth. Further investigation of colocalization of FRYL to P-bodies will
be carried out with co-immunofluorescence with AGO2, a protein involved in the RNAi
machinery and known to localize in P-bodies (Eulalio et al., 2007). In addition, siRNA
experiments will be performed to see whether downregulation of FRYL will result in the
same phenotype as the knockouts, i.e. no localization in P-bodies. The knockdown and
colocalization with AGO2 experiments will reveal whether FRYL protein indeed localizes
to P-bodies.
Moreover, a study showed an indirect connection of FRYL to the Hippo pathway through
immunoprecipitation of Hippo genes (Couzens et al., 2013). FRYL was co-immunoprecipitated
with SLMAP, a component of the STRIPAK complex. SLMAP has been shown to be
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connected to the central Hippo kinases MST1/2 (Couzens et al., 2013). STRIPAK com-
plexes play roles in many biological processes. Interestingly, the STRIPAK complex with
PP2A (Protein phosphatase 2) has been proposed to be a negative regulator of the Hippo
pathway (Ribeiro et al., 2010). The above suggests that FRYL may indeed be connected
with the Hippo pathway. Investigation of YAP activation will indicate if there is such
a connection. If YAP gets activated (or stays activated) in FRYL knockout cell lines in
conditions that would normally be inactive, then the phenotype of enhanced growth in
the transformation screen as well as in the no-selection growth screen can be explained.
Independently of the mechanism of FRYL action in transformation, FRYL was also
enriched in the no-selection screen. This indicates that FRYL knockout clones prolifer-
ate faster than the rest of the knockouts, pointing to an acceleration in the cell cycle.
Similarly to the NF2 deficient clones RPETP53-/- , accelerated growth seems to result in
increase of SCNAs. This was evident only in the RPETP53-/- but not in the RPEWT and
RPETP53-/-, hyperploid cells. An explanation for the WT cells is similar to NF2 deficient
clones, where functional p53 protein is the likely explanation of no SCNA acquisition.
As for the hyperploid cells, extra chromosomes might result in inefficient modification of
all FRYL alleles and thus I could not detect any complete knockouts.
In summary, I envision two possible functions of FRYL: involvement in cell division
– presumably with a role in P-bodies – and regulating the Hippo pathway. The no-
selection growth screen indicates that FRYL knockouts indeed are more represented in
the final population which points to FRYL influencing cell growth. I will further test
these possibilities using a variety of cell biological experiments, comparing WT cells to
the deletion or depletion of FRYL.
Collectively, the sequencing results (as depicted in Fig. 3.11) point to a general mecha-
nism of SCNA acquisition: accelerated growth. As described already for NF2 and FRYL,
both had acquired at least one SCNA in the RPETP53-/- cell lines but not in the WT
cells. Similarly PTPN14 as well as RNF7 (a component of the SCF E3 ubiquitin ligase)
had SCNAs in several sequenced clones in the RPETP53-/- cell line. In total 29 cells out
of 69 sequenced cell lines acquired SCNAs (none for RPEWT, 14/20 for RPETP53-/- and
15/34 for RPETP53-/-,hyperploid). None were identified in the RPEWT cells, indicating the
importance of TP53 inactivation for SCNA accumulation. Also, apart from C6orf222
and TMEM184A, all remaining genes sequenced (AHR, NF2, FRYL, PTEN, PTPN14,
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RNF7, TSC1 ) were enriched in the no-selection growth screen. From these genes TSC1
showed no SCNA accumulation, and AHR only had one clone to carry an SCNA. Despite
this, for the remaining genes at least three clones harboring a SCNA were detected in
the TP53 deficient cell lines. This suggests that these genes, which accelerate growth,
may indirectly lead to SCNA acquisition. Hence, the mechanism of SCNA formation in
the tested knockouts is an indirect consequence of accelerated progression through the
cell cycle resulting to insufficient time to repair potential errors.
From the transformation screen, NF2, PTPN14, PTEN, SERPINB2, FRYL and AHR
were all verified in two different cell lines, retina and mammary epithelial cells. These
results indicate that the transformation potential of these genes are not specific to a cell
line but are able to drive transformation in different cell lines of epithelial origin.
Moreover, the no-selection growth screen was conducted in order to evaluate whether
the results from the transformation screen are specific to transformation or whether
they are dependent on activation of proliferation pathways. Interestingly, similar to
the transformation screen, several Hippo pathway genes were enriched. One candidate,
TAOK1, was highly enriched, but not in the transformation screen, indicating it as a
candidate that is growth specific but not transformation specific. This hypothesis needs
to be tested with a soft agar assay to assess whether the cells can grow unattached to a
surface. Next, mTOR pathway genes TSC1, TSC2 and PTEN were all enriched in the
no-selection growth screen just as in the transformation screen. Lastly, the enrichment
of genes related in the ubiquitin pathway and specifically to the neddylation pathway
was interesting. E2 ligases, UBE2F and UBE2M, were enriched in RPETP53-/- and
RPETP53-/-, hyperploid cell lines as well as CUL3, a cullin activated by these E2 ligases
with NEDD8 (the neddylation protein). Active CUL3 promotes ubiquitin transfer and
degradation of proteins. These proteins are important for the degradation of proteins
involved in cell cycle progression, indicating a driver role in the cells cycle (Petroski and
Deshaies, 2005; Soucy et al., 2010; Tateishi et al., 2001). Knockouts of these ubiquitin
related genes point to accelerated growth and hence may be potential tumor suppressors.
Lastly, the mutational frequency of the top candidates from all the screens conducted
in actual tumors was assessed through analysis of the cancer genome atlas (TCGA).
Only PTEN was highly mutated across all cancers (10%) and up to 65% in UCEC,
which is expected as a known tumor suppressor gene. Other tumor suppressors such
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as TCS1, TCS2, LATS1 and NF2 had mutational frequencies up to 6.6% but only in
specific cancers analyzed. Interestingly FRYL had higher mutation rates from the known
tumor suppressors tested, even further supporting its involvement in cancer. Together
with the tumor promoting role and transformation potential FRYL can be suggested as a
potential novel tumor suppressor gene. AHR and ARNT together had higher mutational
frequencies in some cancers but not across all cancers in general, therefore these genes
may be cancer specific. Further analysis needs to be conducted to find out whether these
mutations are inactivating the genes. Finally, from the ubiquitination pathway KEAP1
was highly mutated, which also has been suggested to play a role in cancer through NRF2
stabilization and handling oxidative stress. In summary, the selected genes have relatively
high mutation frequencies in specific cancers suggesting their possible involvement in
tumor progression.
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3.4 Conclusions
The screens carried out in this study were designed to identify contributors to cell growth
under different conditions, which may be potential tumor suppressors. Both the trans-
formation screen as well as the no-selection growth screen identified known tumor sup-
pressors as well as novel genes that regulate cell growth. Two pathways were highlighted
from both screens: the Hippo pathway and the mTOR pathway. The latter was also
found to have an epistatic interaction with TP53, since these genes were only identified
in the TP53 knockout background but not in the wild type cells. The mTOR TP53
genetic interaction has already been described, indicating that the screens can identify
epistatic interactions.
From the transformation screen, a set of genes was selected for in depth investigation.
The selection was based on positive controls, potential epistatic interactions and novel
candidates. The selected genes were individually verified for their transformation poten-
tial. To further support the transformation effect of the selected genes, six genes, three
controls and three candidates, were able to transform additionally mammary epithelia
cell lines, MCF10A and MCF10A TP53-/- . This result shows the transformation potential
of these genes in different epithelial cell types, indicating that they are not cell specific.
Also many of the identified genes play important roles in several pathways. For example
NF2, acts as an activator of the Hippo pathway and suppressor of anchorage dependent
growth. Therefore, it was not a surprise that NF2 knockouts were highly enriched in
all screens, since it promotes growth in multiple ways. PTPN14 was also enriched in
all screens which is also connected to the Hippo pathway. Moreover, PTPN14 was only
recently described as a tumor suppressor in a basal cell carcinoma. Here I further support
the role of PTPN14 in promoting growth in two different cell types.
From the remaining candidates I focused on AHR and FRYL. AHR has shown to en-
hance tumorigenesis by constitutive activation as well as downregulation. The knockout
screen highlighted the role of AHR disruption, where it enhanced growth and promoted
transformation. The latter was also verified in two different epithelial cell lines showing
that it is not cell specific. Apart of AHR’s enrichment in the no-selection growth screens,
astonishingly ARNT, the protein that binds and transfers AHR protein to the nucleus,
was also enriched. This even further suggests the importance of AHR and specifically
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the complex AHR-ARNT for growth regulation. AHR was suggested to activate the
tumor suppressor RB protein, that inhibits progression of the cell cycle and also AHR
was shown to promote degradation of CTNNB1 protein, which promotes growth. These
findings indicate multiple functions of AHR to control cell growth and proliferation and
suggest AHR as a potential tumor suppressor.
Besides AHR, FRYL was also enriched in the transformation screen but was specific to
TP53 knockout cell lines, which may indicate an epistatic interaction between FRYL
and TP53. Confirming its growth promoting function even further, FRYL was enriched
in the no-selection growth screen. Since the wild type screen has not been performed
yet, the epistatic interaction of FRYL and TP53 cannot be confirmed in the no-selection
growth screen. This study suggests FRYL protein to potentially localize in P-bodies and
the literature suggests a connection of FRYL with the Hippo pathway (Couzens et al.,
2013). How FRYL promotes growth through P-bodies is still under investigation. As for
the connection to the Hippo pathway, I will test whether FRYL knockouts lead to the
activation of the YAP protein, the executor of the Hippo pathway. FRYL has not been
characterized yet, making it an interesting candidate to investigate its effect in promoting
growth and transformation and classifying it as a potential tumor suppressor.
Furthermore, apart from the Hippo and mTOR pathways being enriched in the no-
selection growth screen, ubiquitin mediated degradation genes were also enriched. Cer-
tain genes, also specific to the neddylation pathway (part of the ubiquitin pathway),
were connected in the same cascade indicating that either one of them being disrupted
may result in promoting growth. Whether these genes also promote transformation still
needs to be investigated.
Both transformation screen and no-selection growth screen complement each other. The
transformation screen revealed tumor suppressors as expected, but also identified po-
tential new contributors to cell transformation. The no-selection growth screen also
revealed known tumor suppressors and contributors to cell growth, some of which were
also enriched in the transformation screen. Therefore transformation can be considered
to be highly influenced by constant growth signaling. In addition, several candidates
have more than one function, many of which result in accelerated growth. Therefore,
dysfunctional genes that result in enhanced growth and override anchorage dependence
will be more enriched than other genes. Hence, the transformation screen can be biased
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to select transformed clones that cover these two functions. Nevertheless, it revealed new
candidate genes, which have not been previously suggested as promoters of growth and
as tumor suppressors. Furthermore, the tumor suppressor role of the novel candidates
can be supported by the higher mutational frequencies observed in tumors from TCGA,
which may result in inactivation of the gene. A summary of the results is depicted in
Figure 3.14, which indicates the targets and interactions of the candidates.
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Figure 3.14: Summary of candidates and their role in pathways. All candidates
result in promoting growth, indicating it as a large attribute to cell transformation and
furthermore cancer progression. (Beli et al., 2012; Chen and Chen, 2016; Chien et al.,
2005; Collins et al., 2013; Couzens et al., 2013; Croucher et al., 2008; Hariharan, 2015;
Hasumi et al., 2015; Jaramillo and Zhang, 2013; Johnson and Halder, 2014; Mihaylova
and Shaw, 2011; Murray et al., 2014; Ooi et al., 2013; Rattan et al., 2010; Ren et al.,
2014; Rizzo et al., 2008; Samant et al., 2014; Soucy et al., 2010; Starheim et al., 2009;
Wang et al., 2012, 2009; Wilson et al., 2014)
In conclusion, the screens identified known tumor suppressors as well as novel candidates.
Furthermore, I found that anchorage independent growth, which is an indicator of cell
transformation, is largely driven by accelerated cell growth. The fact that the same
candidates in the no-selection growth screen were most enriched in the transformation
screen indicates that fast growth itself can be sufficient to transform cells. How exactly
the novel candidates promote cell growth, is still under investigation. Several follow-up
experiments need to be conducted in order to understand the mechanisms of actions of
genes and pathways and how their deregulation leads to uncontrolled growth.
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Eventually the goal of this project is to transfer this knowledge from basic research to
medical applications. By identifying novel tumor suppressors and their mechanisms of
action, we can shed light into novel mechanisms of cancer initiation and progression.
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Final Conclusions
In this thesis I investigated mechanisms of cancer progression using CRISPR/Cas9-based
approaches. I used targeted approaches to decipher the mechanism of oncogene activation
through enhancer hijacking and a systematic unbiased approach to identify potential
tumor suppressors.
In the first project (Chapter 2) I sought to investigate a mechanism involving struc-
tural changes in the genome relocating enhancers to nearby genes and leading to their
increase in gene expression, described as enhancer hijacking (EHJ). From analysis of
cancer genomes I was involved in (Weischenfeldt, Dubash, Drainas et al., in revision),
we identified IGF2 and IRS4 to be implicated in EHJ and further investigated their
mechanism of activation. To this end, I recreated rearrangements associated with IGF2
and IRS4 overexpression using CRISPR/Cas9-based technology in relevant cell lines.
We screened over 3000 clones and obtained 37 clones verified by PCR. The strategy
used was similar to recent published work (Kraft et al., 2015; Li et al., 2015) with
some differences that allowed us to screen clones more efficiently. From our clones that
harbored the rearrangement according to PCR and Sanger sequencing validation, three
cases were further verified also by whole genome sequencing. Although we successfully
engineered the rearrangements, overexpression of the genes was not observed. This could
be dependent on the cell context and chromosomal epigenetic state or in addition indicate
a more complex mechanism of activation. Further experimental work in in vivo, for
example in mouse, may overcome these limitations and the applied modification can
target the correct cell type and chromosomal state.
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Another aim I achieved in this chapter was to address the oncogenic role of IRS4. IRS4
was identified as the major EHJ candidate from the analysis across several cancers,
especially in lung squamous carcinoma. As IRS4 has not been described as an oncogene,
we showed the growth promoting role IRS4 in tumor xenografts in mice, indicating its
oncogenic properties. Hence, this result further supports IRS4 as a potentially novel
oncogene. This work is part of a manuscript we recently submitted (Weischenfeldt,
Dubash, Drainas et al., in revision).
Apart from oncogene activation, I investigated tumor suppressors using genome wide
screens (Chapter 3). The aim was to conduct CRISPR/Cas9-based screens and identify
novel tumor suppressors. I used two approaches, with anchorage independent growth
as a selection barrier (transformation screen), and a growth assay without any selection
(no-selection growth screen) and used epithelial cells in these screens. Many of the
enriched genes in the transformation screen were known tumor suppressors indicating
the reliability of the screen. Surprisingly, similar genes were also the highly enriched in
the growth screen. This result indicates that promoting growth is a major contributor
for overcoming anchorage dependency. Furthermore it supports that the potential novel
candidates may indeed play tumor promoting roles since they were identified by two
independent assays along with known tumor suppressors.
Another aim in this chapter was to identify potential genetic interactions with TP53.
From the candidates identified, a previously known genetic interaction between TP53
and mTOR pathway was confirmed. I also identified two novel tumor suppressors; AHR
that was enriched in all screens and FRYL that was enriched in the TP53-/- cells, in-
dicating a possible genetic interaction. Moreover, the transformation ability of these
candidates were verified, also in different cell lines, showing that the genes may promote
anchorage independent growth across different cell lines. AHR and FRYL were also
found to be mutated in cancer genomes and together suggesting these genes as potential
tumor suppressors.
During my PhD I was also involved in the development of a tool to analyze the screen
data. We developed ScrispR, which uses information of random and fixed effects from
the assay, an approach that has not been used before to our knowledge, for the analysis of
such screens. A future outlook is the comparison of this tool with other recently developed
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tools, which are mostly based on indirect methods to account for gRNA variability (Li
et al., 2014b; Winter et al., 2015).
In conclusion, during my PhD work, I generated targeted rearrangements in the genome
and revealed that the mechanisms of EHJ are more complicated than initially anticipated
and likely context specific. Furthermore, I contributed to the discovery of IRS4 as a
potential oncogene and I identified potential tumor suppressors from CRISPR/Cas9-
based genome wide screens. These results will increase our understanding of tumor
formation mechanisms.
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Chapter 5
Materials and Methods
5.1 Experimental Procedures Related to All Chapters
5.1.1 Cell lines
The cell lines used for all projects and relevant information are indicated in Table 5.1.
All different medias were supplemented with Antiotic-Antimycotic (Thermo Fischer Sci-
entific). The media for the MCF10A cell lines contained additionally 5% cholera toxin,
1 ng/mL human insulin, 10 µg/mL epidermal growth factor, 10 ng/mL hydrocortisone.
All cell lines were regularly checked for mycoplasma contamination.
5.1.2 CRISPR design
CRISPRs were designed according to the webtool (http://crispr.mit.edu/) and were fur-
ther selected based on their sequence adjacent to the PAM region (Doench et al., 2014).
The least favored sequence is C-TGG-G with in any case eliminating any PAMs that
follow three guanines. These restrictions were based according to the cutting efficiency
(Doench et al., 2014). Selected CRISPRs (or gRNAs) were cloned and their cutting effi-
ciency was tested with the surveyor assay (Section 5.3.8,Integrated DNA Technologies).
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Table 5.1: Cell lines used in study. FBS: Fetal Bovine Serum, HS: Horse Serum. ND:
not determined.
Cell line Puromycin Media Distributor
RPE-1 WT 5 µg/ml DMEM/F12-FBS ATCC
RPE-1 TP53-/- 10 µg/ml DMEM/F12-FBS (Mardin et al., 2015)
RPE-1 TP53-/-,hyperploid 10 µg/ml DMEM/F12-FBS (Mardin et al., 2015)
MCF10A WT 0.5 µg/ml DMEM/F12-HS+ ATCC
MCF10A TP53-/- 0.5 µg/ml DMEM/F12-HS+ This study
HEK293FT ND DMEM-FBS Thermo Fischer
HCC15 ND RPMI-FBS DSMZ
H520 ND RPMI-FBS ATCC
H2170 ND RPMI-FBS ATCC
5.1.3 CRISPR cloning
The CRISPR sequences were cloned according to a modified protocol from Shalem et al.
(2014) to the vectors of choice (see Table 5.2). Each CRISPR pair was annealed by
adding 1 µl of each CRISPR primer, 1 µl 10X T4 Ligation Buffer (NEB) up to 10 µl
H20. Then the CRISPRs were placed in the thermocycler and incubated for 30 minutes at
37 oC, heated to 100 oC and ramped down by 1 oC/sec to room temperature. In parallel,
the vector was digested with the appropriate restriction enzyme to allow annealing with
the gRNAs. The annealed guides are then diluted 1:100. The ligation reaction is set
up according to Table 5.3 and incubated for ten minutes. Then we transform Stbl3
chemically competent bacteria (Thermo-Fischer Scientific). The bacteria are thawed on
ice and 2.5 µl from the reaction are used with 25 µl of the bacteria. The mixture is
incubated on ice for 30 minutes and then a heat-shock for 60 seconds is applied at 42
oC. After the heat-shock the bacteria is placed back on ice for five minutes. 250 µl
of SOC media is then added and the cells are incubated at 37 oC for one hour. The
bacteria are then pelleted at 4000rpm for three minutes and are plated on agar plates
with a selection marker (Ampicillin for lentiCRISPRv2 and pX330 vectors). The next
day individual clones are picked and cultured in 5 ml LB liquid cultures. The day after,
0.5 ml is mixed with 60% glycerol to prepare a bacteria stock. The remaining sample is
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pelleted and plasmid DNA is isolated (Qiagen). DNA pellets are then sent for Sanger
sequencing with the appropriate primers to verify the cloning of the guide sequence.
Table 5.2: Vectors used in study
Vector Distributor or Specification
pX330 Addgene ref: 42230
pX330-P2G pX330 with gRNA insertion sites
pLenti-IRS4-Myc-DDK Origene, ref: RC218385L1
pIRES2-AcGFP1 Takara-Clonetech
pLenti-IRS4-Myc-DDK-IRES-GFP pLenti-IRS4-Myc-DDK with IRES-GFP from pIRES2-AcGFP1
pLenti-IRES-GFP Control without IRS4
pDup Construct with homologous arms for IGF2 duplication
pDelA Construct with homologous arms for IGF2 deletion A
pDelB Construct with homologous arms for IGF2 deletion B
pDelC Construct with homologous arms for IGF2 deletion C
pDelD Construct with homologous arms for IGF2 deletion D
pDelF Construct with homologous arms for IGF2 deletion F
psPAX2 Addgene, ref: 12260
pMD2.G Addgene, ref: 12259
lentiCRISPRv2 Addgene, ref: 52961
lentiCRISPRv2-EGFP lentiCRISPRv2 with GFP as a selection marker
Table 5.3: Ligation Reaction
X µl Digested plasmid (50 ng)
1 µl Annealed gRNAs
5 µl 2X Quick Ligase Buffer (NEB)
X µl ddH2O
10 µl subtotal
1 µl Quick Ligase (NEB M2200S) total
11 µl total
5.1.4 Virus production and infection
HEK 293FT cells (Table 5.1) were cultured to 80% confluence in 6-well plates. 1 µg of
vectors psPAX2, pMD2.G and the respective lentiviral vector (see Table 5.2) were mixed
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1:1:1 in OptiMem (Thermo Fisher Scientific) and transfected with Lipofectamine 3000
to the 293FT cells according to the manufactures protocol.
Virus was added directly to the media of the cells with the addition of 8 µg/mL polybrene
(Sigma-Aldrich) (Davis et al., 2002). The cells were then centrifuged at 2000rpm for
hours hours (spinfection). After centrifugation the media was replaced with fresh media.
According to the type of selection the virus vector carried, the cells were either treated
the next day with puromycin, or were sorted according to their GFP intensity three to
four days later.
5.1.5 Immunoblotting
Cells were grown in 6-well plates until confluence. The cells were then trypsionized,
washed twice with PBS and could be stored at -80 oC with snap freezing. For every
one million of cells (roughly one confluent 6-well) 50 µl of RIPA buffer was added (10
mM Tris-Cl (pH 8.0) 1 mM EDTA. 1% Triton X-100. 0.1% sodium deoxycholate. 0.1%
SDS, 140 mM NaCl, 1 mM PMSF). Additionally a protease inhibitor cocktail was added
(Thermo-Fischer Scientific). For whole lysate, the sample was sonicated for 15 minutes
with one minute break intervals at 4 oC (protein extracts were kept always at 4 oC).
Protein concentration was measured using Bradford assay (Bio-Rad) as described below.
A 96-well plate was prepared with BSA concentrations ranging from 5 µg/µl to 40 µg/µl
in triplicate (1 µl of RIPA buffer was added to each solution and then 200 of 1x Bradford
solution was added to each well). 1 µl of protein solution in triplicate was added and then
200 µl of the Bradford solution was added. The plate was incubated for five minutes at RT
and then was measured at 595nm. The BSA slope was used as a reference to estimate the
protein amount of the samples. For each sample 4x sample buffer (Bio-Rad) was added
and the samples were then boiled for five minutes at 99 oC. Then the samples were stored
at -20 oC. Approximately 20 µg of protein were added to a 4–20% gradient gel (Bio-Rad)
and ran at 180V for one hour. The gel was then transferred to a nitrocellulose membrane
by a Bio-Rad transfer system and ran according to the manufacturer’s pre-settings. After
the transfer the membrane was incubated for 30 minutes in 10% low fat milk in TBS-T
(50 mM Tris pH 7.5, 150 mM NaCL, 0,1% Tween). Then the membrane was washed
three times with TBS-T. Antibodies were added to 5% milk in TBS-T and the membrane
was then incubated overnight at 4 oC. The next day the membrane was washed three
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times with TBS-T. The secondary antibody was added to 5% milk in TBS-T and the
membrane was incubated for one hour. The membrane was washed three times with
TBS-T and horseradish-peroxidase substrate (Bio-Rad) was added to the membrane.
After five minutes the membranes were photographed for chemiluminescence (Bio-Rad).
5.1.6 Long-range paired-end sequencing (MP-seq)
Long-range (or ‘Mate-pair’) DNA library preparation was carried out using the Nextera
Mate Pair Sample Preparation Kit (Illumina). In brief, 4 µg of high molecular weight
genomic DNA were fragmented by the Tagmentation reaction in 400 µl, followed by the
strand displacement and AMPure XP (Agencourt) cleanup reaction. Samples were size
selected to 4-6 kb with a gel step following the Gel-Plus path of the protocol. 300-550ng
of size-selected DNA were circularized in 400 µl for 16 hours at 30 oC. The library was
then constructed after an exonuclease digestion step to get rid of remaining linear DNA,
fragmentation to 300-700 bp with a Covaris S2 instrument (LGC Genomics), binding to
streptavidin beads and Illumina Truseq adapter ligation. The final library was obtained
after PCR for one minute at 98 oC, followed by nice cycles of 30 seconds at 98 oC, 30
seconds at 60 oC, one minute at 72 oC and a final five minutes at 72 oC step. Deep
sequencing was carried out with the Illumina HiSeq2000 (2x101bp) instrument using v3
chemistry to reach an average physical coverage of 20-30x. After sequencing, the reads
were aligned to the hg19 assembly of the human reference genome. Library preparation
performed by Dr. Adrian Stütz and Benjamin Reader. Text adapted from Weischenfeldt,
Dubash, Drainas et al. (in revision).
5.1.7 Mass-low coverage whole genome sequencing (LC-WGS)
Libraries were prepared using NEB Ultra kit (New England Biolabs) according to man-
ufacturers specifications. Libraries were then sequenced on a Hiseq 2000 (Illumina).
Library preparation performed by Dr. Adrian Stütz and Benjamin Reader.
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5.2 Experimental Procedures Related to Chapter 2
5.2.1 Flow cytometry
Transduced HCC-15 cells were sorted for GFP expression on a MoFloXDP cell sorter
(Beckman Coulter Inc) equipped with a Coherent Innova 90C Argon ion laser (Coherent
Inc.), tuned to 488 nm at 200 mW. Cells were sorted using a 100 µm Nozzle while running
BD FACSFlow as sheath at 20 psi/RT. Forward and side scatter height and area signals
were used for gating of live cells and singlets. GFP fluorescence was detected using a
530/40 nm bandpass filter combined with a 488 notch filter. GFP positive cells were
sorted in purity mode (one drop envelope) into 6-well or 96-well dishes with culture
media respectively. In order to measure GFP intensity HCC-15 cells were run through
LSR-Fortessa SORP instrument (BD Biosciences) with a 488 nm laser (530/30 BP). All
post acquisition analysis was done with FlowJo 10.0.8 (Tree Star, Inc). Text adapted
from Weischenfeldt, Dubash, Drainas et al. (in revision).
5.2.2 IRS4 vectors and virus preparation
HCC15 cell line was purchased from DSMZ and cultured in RPMI 1640 medium (Thermo
Fisher Scientific) supplemented with 10% FBS (Thermo Fisher Scientific) and Antibiotic-
Antimycotic (Thermo Fisher Scientific). An IRS4 overexpressing vector, pLenti-IRS4-
Myc-DDK, was purchased from OriGene. An IRES-eGFP sequence was cloned from
a pIRES2-AcGFP1 vector (Takara-Clonetech) into the pLenti-IRS4-Myc-DDK vector
using In-Fusion HD cloning kit (Takara-Clonetech) and it is referred as pLenti-IRS4. We
used the following primers for this purpose: F-GGCCGCGGTCTGTACActtcgaattctgca-
gtcgacg; and R-GAATCCTACTTGTACAtcacttgtacagctcatccatgcc. The control vector
was created by removing IRS4-Myc-DDK by restriction enzyme digest with EcoRI and
it is referred as pLenti-empty. Plasmids used for lentivirus production were pMD2.G
(VSV-G envelope) and psPAX2 (2nd generation lentiviral packaging plasmid); both gifts
from Didier Trono - Addgene plasmids ref: 12259 and 12260. Lentivirus production was
conducted by transfection with Lipofectamine 3000 Reagent (Thermo Fisher Scientific)
of equal amounts of pMD2.G, psPAX2 and pLenti-IRS4-Myc-DDK-IRES-GFP/pLenti-
IRES-GFP, in 293FT cells (Thermo Fisher Scientific) according to the manufactures
protocol. Cells were transduced with produced virus with the addition of 8 µg/mL
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polybrene (Sigma-Aldrich) by spinfection (centrifuge 2000 rpm for two hours) with the
produced virus and were enriched by sorting according to eGFP intensity (see Flow
cytometry methods). All cell lines were regularly checked for mycoplasma contamination.
Text adapted from Weischenfeldt, Dubash, Drainas et al. (in revision).
5.2.3 Mouse injections
One million transduced HCC15 cells were suspended in DMEM mixed 1:1, v/v with
Matrigel (BD Biosciences) and subcutaneously implanted into both flanks of nude mice
(Charles River Laboratories, NMRI-Foxn1nu /Foxn1nu (homozygous) male mice; eight
weeks old at time of injection). The total number of tumors were N=8 for each cell line
(i.e. using four mice for each line, whereby we performed experiments in both flanks in
each mouse). While at this sample size effect sizes are not robustly estimated, differences
in tumor growth became readily evident. Mice were randomly assigned into two groups
and tumor sizes were measured twice weekly in two dimensions (length and width).
Tumor volumes (V) were calculated as: V (cm3) = 0.5 X (length X width2). Mice were
euthanized once the biggest tumor volume was 2 cm3. Mice were housed and maintained
according to animal use guidelines at EMBL Heidelberg. Both mouse grouping as well as
tumor volume measurements were blinded. Text adapted from Weischenfeldt, Dubash,
Drainas et al. (in revision).
5.2.4 qPCRs
Single-stranded cDNA was synthesized from 500 ng of total RNA using the SuperScript
III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen) according to the manu-
facturers’ protocol.
The qPCR primers were designed using the online Primer3 Plus program (Untergasser
et al., 2007) with the qPCR settings activated. Primer sequences are IRS4_F: CCCACA-
CATGAGCAGAGAGA, IRS4_R: CTGACTGTCTGGGTTCAGCA, Globulin_F: TA-
CATGTCTCGATCCCACTTAACTAT, Globulin_R: AGCGTACTCCAAAGATTCAG-
GTT, IGF2_F: TGGCATCGTTGAGGAGTGCTGT and IGF2_R: ACGGGGTATCT-
GGGGAAGTTGT. All primers were tested by running a standard curve and requiring
the primer efficiency to be between 90-100% and as close as possible to that of the house
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keeping primer pair. The primer efficiency for globulin was 91.3%, 91.6% for IGF2 and
95.6% for IRS4. In addition, a single and discrete peak was detected in the melt curve
analysis for all primers tested. The qPCR experiments were performed on a StepOnePlus
96 Fast machine (Applied Biosystems) in 20 µl using a 96-well plate. The mastermix
contained 10 µl 2xSYBR Green PCR Master Mix (Applied Biosystems), 0.4 µl of each
primer (10 µM), 2.5-5 ng of sample cDNA in 5 µl, and 4.2 µl nuclease free H2O. The
reaction program was run in default ramping speed mode and cycling conditions were 10
min at 95 oC, 40 cycles of 95 oC for 15 seconds and 60 oC for one minute, followed by a
melting curve stage. Non-template controls were included in all experiments, replacing
cDNA with H2O, and typically resulted in no detection at all. The results were analyzed
using the StepOne analysis software v2.3 (Applied Biosystems). Relative expression lev-
els for IGF2 and IRS4 were calculated after normalization to the house keeping gene
globulin using the ∆∆-Ct method in Microsoft Excel. Experiment performed by Dr.
Adrian Stütz. Text adapted from Weischenfeldt, Dubash, Drainas et al. (in revision).
5.3 Experimental Procedures Related to Chapter 3
5.3.1 CRISPR soft-agar screen protocol
In order to perform the transformation screen based on CRISPR/Cas9 and soft agar the
following steps take place. Firstly, the virus needs to be prepared in large amounts to be
used in the screen. Next, the multiplicity of infection (MOI) needs to be calculated for
optimal virus use. Afterwards the infection of the screen takes place with the estimated
MOI. Then the clones that were selected for virus uptake are subjected to soft agar. Cells
collected before and after agar selection have their DNA extracted and then libraries
containing the gRNA information of each population are prepared and sequenced. The
next section describe these steps in detail.
5.3.1.1 Virus preparation
The GeCKOv2 library was purchased from Addgene and was amplified according to
Shalem et al. with small modifications (Shalem et al., 2014). For virus production two
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5-layer flasks (Corning) were seeded with 25 million 293FT cells each in DMEM com-
plete media (+10% FBS, NEAA, pyruvate, glutamine, Antibiotic-antimycotic - (Thermo
Fischer Scientific)). The next day, the media was removed and 110 ml of fresh DMEM
complete media was added. For each flask, 500 µl of P3000 reagent (Lipofectamine 3000
kit – Thermo Fischer Scientific) was diluted in 20 ml OptiMEM (Thermo Fischer Sci-
entific) with 100 µg of GeCKOv2 library (Addgene - ref:1000000048), 50 µg of pMD2.G
(Addgene – ref: 12259), and 75 µg of psPAX2 (Addgene - ref: 12260). 500 µl of Lipo-
fectamine 3000 (Thermo Fischer Scientific) was added to 20 ml of OptiMEM and after
five minutes was mixed with the DNA-P3000 solution. The complete mixture was in-
cubated for ten minutes at room temperature and then was added to each flask. After
60 hours, the media was collected and centrifuged at 3,000 rpm at 4 oC for ten minutes
to pellet cell debris. The supernatant was then filtered through a 0.45 µm low protein
binding membrane (Millipore Steriflip HV/PVDF). To achieve 100-300X concentration
of the pooled library, the virus was ultracentrifuged 24,000 rpm for two hours at 4 oC
(Beckman Coulter). Media was removed and the pellet was resuspended overnight at 4
oC with agitation in 8 ml of DMEM supplemented with 1% BSA. Stocks of 50 µl were
prepared, for multiplicity of infection testing and 500 µl aliquots for use. The aliquots
were stored at –80 oC.
5.3.1.2 Multiplicity of infection (MOI)
To achieve this one million cells with 3 ml of media were plated in each well of a 6-well
plate 16 hours before transduction. Then, the media was aspirated from each well and
2 ml of media supplemented with polybrene (8 µg/µl) was added. To each well 2 µl, 7
µl, 15 µl, 25 µl of virus was added. The remaining wells served as positive and negative
controls. The plate was then centrifuged for two hours at 37 oC at 2000 rpm. After
centrifugation, the virus-containing media was replaced with fresh media and the cells
were allowed to recover for one day. The next day the cells from each well were split
into 15 cm dishes with media supplemented with puromycin (Table 5.1). Puromycin
was also added to the negative control but not to the positive control in order to check
for cell viability. Then the cells were grown for three days and the number of cells
was counted for each condition. The MOI was determined by dividing the amount of
cells in each condition with the amount of the positive control cells (Fig. 5.1). A MOI
of approximately 20% was achieved for each experiment. Over 30-40% MOI was not
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observed, perhaps due to the toxicity of the virus to the cells, therefore a preferable
range was close to 20%.
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Figure 5.1: Example of multiplicity of infection (MOI) determination.
RPETP53
-/-, hyperploid cells were infected with deferent amounts of the produced virus.
After infection the cells were selected with puromycin. The percentage of cell survival
in comparison to cells with no selection was calculated and considered as the MOI. A
MOI of approximately 20% is selected for the virus screens.
5.3.1.3 Screen and infection
98 million cells were grown per library per replicate. RREWT and RPETP53-/- were
aliquoted to one million cells per well into 6-well plates, as for RPETP53-/-, hyperploid were
0.5 million cells per 6-well. The MCF10A and MCF10ATP53-/- cells lines were plated
as two million cells per 6-well. Lastly, two 6-well plates were used as positive (virus
and no puromycin – for MOI estimation) and negatives controls (no virus, puromycin).
Each well contained 2 ml of media. The next day, the media was removed and replaced
with new media supplemented with polybrene and the appropriate virus amount (this
can be achieved easily by making a master-mix and using a 15 ml pipet). Cells were
spinfected for two hours at 37 oC at 2000 rpm. Then the media was replaced and the
cells recovered for one day. The following day 12 wells were pulled together into one 5-
layer flask with media with puromycin. Eight 5-layers were needed in total. Positive and
negative controls were planed in 15 cm dishes. After three days, the cells were collected,
filtered in a 70 µm cell strainer (Falcon) and counted to estimate the complete number
of cells that survived. Up to 80 million cells were used for soft agarose selection. When
less, two thirds, was used for agarose selection. The rest was frozen in order to have a
representation of gRNAs before agar selection.
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5.3.1.4 Agar selection
In order to prepare the agarose layer, 2x media (Thermo-Fischer Scientific) was prepared
and filtered with a 0.22 µm filter (Millipore). Then it was mixed 1:1 (at 37 oC) with 0.7%
agarose (autoclaved). 8 CellSTACK flasks (636 cm2 growth area) with low attachment
surface (Corning) were used for each screen. Approximately eight to ten million (through
a strainer in order not to form clumps) cells per stack with 150 ml of final volume were
used. The flasks were let in room temperature for 30 minutes to solidify. After the agarose
solidified 50 ml of media was added. The cells were incubated then for at least five weeks.
After incubation and colonies appeared in the soft agar, the cells were collected into a
beaker and pipetted several times in order to break the agarose layer. 100 ml of media
was added per flask and pipetted and then approximately 70 ml was added to 5x15 cm2
dishes. Two day later the 5x15 cm2 dishes were pipeted to 6x15 cm2 dishes after the
addition of 70 ml more media. Any floating colonies were collected and plated in an
individual plate. Although there was a loss of cells that did not attach to the plate, an
acceptable amount of cells attached to the plate. The cells were then incubated for five
to seven days in order to allow them to attach. For collection the dishes were washed
twice with PBS then trypsinized, pelleted and frozen at -80 oC.
5.3.1.5 PCR amplification of GeCKO libraries and sequencing
Genomic DNA was isolated with QIAamp DNA Blood Maxi Kit and quantified with
Qubit. Then eight reactions of 0.5 µg DNA per reaction were prepared (Table 5.4) for
a first PCR amplification step with the settings shown in Table 5.5. The samples were
pooled together into two vials (four samples in each) and the PCR reaction was purified,
eluted in 30 µl H2O and quantified. Four reactions for the secondary PCR reaction were
prepared with 6 µl of DNA per reaction (Table 5.4).
The primers used for the reactions are depicted in Table 5.6. After the second PCR all
reactions were pooled together, purified using AMPure beads (Beckman Coulter) and
eluted in 30 µl. All samples were then run in a 1% agarose gel for one hour. A band
of approximately 390 bp was cut, purified and quantified with Qubit. All samples were
pooled appropriately and submitted for sequencing.
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Table 5.4: PCR mix used for GeCKO library amplification
Hercules mix (1x of 50 µl)
Buffer 10 µl
dNTPs 0.5 µl
Primers 1.25 µl each
Enzyme 0.5 µl
H2O up to 50
Table 5.5: PCR run settings
Hercules PCR reactions
cycle temperature time
1 98 oC 2:00
2 95 oC 0:20
3 62 oC 1st (60o 2nd) 0:20
4 72 oC 0:30
5 GoTo 2 17 times1st, (7 times 2nd)
6 72 oC 3:00
7 12 oC forever
5.3.2 Mapping raw representation of gRNAs and downstream analysis
Short reads were initially pre-processed to remove barcodes and afterwards aligned to
the self-constructed guide reference database (n=123,411 contigs) using Subread, a short-
read alignment program in R (Liao et al., 2013). The total number of aligned reads per
guide sequence was then used as the quantification measure. ScrispR takes raw read
counts per guide as input and generates initial quality control plots to evaluate the
reproducibility of the screen. Raw read counts are adjusted for sequencing depth by
scaling guide counts by the total number of sequenced reads that mapped onto the full
guide sequence database. Differences between conditions, in this case before and after
transformation, for each guide are evaluated using a mixed effect model (MEM) that
is implemented in the lme4 R package (Bates et al., 2015) (see section 3.2.2). Note,
log-transformation is applied to satisfy the normality assumption of residuals. Finally,
normal distributions are used to approximate nominal model P -values for each gene.
The False Discovery Rate (FDR) procedure by Benjamini-Hochberg is used to account
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Table 5.6: Primers for 1st & 2nd PCR reactions
Primers
Lenti_AF atggactatcatatgcttaccgtaacttg
Lenti_AR cgactactgcacttatatacggttctc
Universal caagcagaagacggcatacgagatcggtctcggcattcctgctgaaccgctcttccga
tctcaacttctcggggactgtgggcga
GeCKO_1 aatgatacggcgaccaccgagatctacactctttccctacacgacgctcttccgatct
-atgcga-tcttgtggaaaggacgaaacaccg
GeCKO_2 aatgatacggcgaccaccgagatctacactctttccctacacgacgctcttccgatct
-cataa-tcttgtggaaaggacgaaacaccg
GeCKO_3 aatgatacggcgaccaccgagatctacactctttccctacacgacgctcttccgatct
-gccg-tcttgtggaaaggacgaaacaccg
GeCKO_4 aatgatacggcgaccaccgagatctacactctttccctacacgacgctcttccgatct
-tga-tcttgtggaaaggacgaaacaccg
for the multiple testing. Genes are scored both by its fold change and FDR corrected
P -values. Genes can be visualized by volcano plots that depict fold change in the x-axis
and P -values on the y-axis.
5.3.3 Candidate verification assay
For each candidate selected from the screen, three gRNAs were selected for verification.
Two of gRNAs were selected showing the highest efficiency in the screen and an additional
one was designed. The gRNAs selected were cloned according to section 5.1.3 and virus
was produced according to 5.1.4. RPE and MCF10A cell lines (Table 5.1) were plated in
96-well plates and were infected with virus when they reached a confluence of 80%. The
cells then were spinfected for two hours at 37 oC at 2000 rpm. After spinfection the cells
were incubated overnight and the next day were split in concentration 3/5 to new 96well
plates. Puromycin selection was conducted according to the concentration depicted in
Table 5.1. After three to five days of selection (according to the negative control), cells
were split in half to low attachment plates (Corning), mixed 1:1 (total volume of 150 µl)
with agarose (0.7%). The remaining half are put back into a normal 96-well plate and
the next day were treated with MTT (see section 5.3.4). The MTT assay estimated the
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amount of cells that were going to be embedded in soft agar. The agarose plate was then
solidified in room temperature for 30 minutes. The solidified plates were then incubated
at 37 oC. The next day a feeder layer of 100 µl of media was added to the wells. The
plates were wrapped with airtight plastic wrap and incubated for one month at 37 oC.
After one month of culture, each well was collected separately to 6-well plates. To allow
better solubilization of the agar, 10 µl solubilization solution (Cell Biolabs) was added
to each well prior collection. The colonies were incubated for one to two weeks - until
colonies visually appeared in the positive control wells (i.e. transformed cell lines). The
6-well plates were washed twice with PBS and crystal violet of concentration of 0.05%
was added for ten minutes in each well. Crystal violet is a violet color chemical that
binds proteins and DNA (Franken et al., 2006). The colonies were colored and each
plate was photographed (S&P Robotics). The data was analyzed by Fiji (Schindelin
et al., 2012) by a code kindly provided by Hernando Martinez Vergara. In brief the code
converts each image to 8-bit and then sets a threshold in order to capture the colonies
(set manually). Then it measures the amount of black and white pixels that correspond
to growth and empty space. This is then output to a csv file, which is then further
processed using “R”. The data is normalized to the highest positive control values (in
these experiments, according to NF2 ) in order to compare growth across experiments.
This is then plotted with barplots with error bars of the standard deviation of the mean
(Fig. 3.9).
5.3.4 MTT assay
MTT solution (Sigma) was prepared to 5mg/ml (10x stock) in PBS and passed through
a 0.2 µm filter. MTT is stored in -20 oC. Cells are cultured in 96-well plates and 10 µ
of MTT solution is added to each well. The cells are then incubated for three hours in
37 oC. Then, all media (with MTT) is aspirated and cells are then left to dry for one
hour. Afterwards, the cells are dissolved in 100 µl isopropanol and the optical density is
measured at 570 nm (and reference over 650 nm).
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5.3.5 Creating TP53-/- cell lines
For each gene, gRNAs targeting within the first exons were designed according to section
5.1.2. Two gRNAs targeting TP53 were then cloned in vector px330-P2G (Table 5.2).
Cells in 10 cm dishes were transfected with Lipofectamine 3000 (Thermo-Fischer scien-
tific) according to the manufacturers protocol. The next day the cells were split into a
15 cm dish and puromycin was added for selection. After two days the cells were single
cell sorted on 96-well plates. Cells clones were then subsequently grown to 6-well plates.
In order to test p53 protein expression, cells were treated one hour with doxorubicin 1.5
µM in order to damage the DNA and induced a DNA damage response. Finally, protein
expression was tested by immunoblotting (Fig. 5.2).
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Figure 5.2: TP53 knock outs in MCF10A cell lines. TP53 in clones 6, 8 and 9 was
successfully disrupted wereas the control and clone 5 exhibit TP53 protein expression.
5.3.6 Immunofluorescence
Cells are grown on glass slides (cover slips) until 95% confluence. Then the cells are
fixed either with formaldehyde 4% in PBS for ten minutes in room temperature or with
methanol for five minutes in -20 oC. After fixation the cover slips were washed once
with PBS and stored in 4 oC. The fixation method depends on the antibody activity,
therefore for initial tests both fixing methods were used. Afterwards, the cells were
treated with 0.1% Triton-X 100 for ten minutes for membrane permeabilization. The
cells were then washed once with PBS, incubated with 10% FBS (Fetal Bovine Serum)
for 30 minutes and then washed with PBS again. Antibody was diluted in 3% BSA
(Bovine serum albumin) in the suggested concentration. Then 10-15 µl (according to
cover slip size) of antibody was added to each cover slip (added on parafilm and at the
cover slip upside down on the solution). The antibody was incubated on the cells for one
hour in a humidified chamber. The cover slips were then washed three times with PBS
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and the secondary antibody (an antibody conjugated to a fluorophore and targets the
species of the primary antibody) was then added, together with 1:10000 HOECHST dye
(DNA binding dye) for 30 minutes. After incubation the cover slips were washed three
times with PBS and the slides were fixed on glass slides with ProLong (Thermo Fischer
Scientific). The cells could then be visualized on a fluorescence microscope.
5.3.7 Sanger sequencing verification
Sanger sequencing was performed by GATC biotec (https://www.gatc-biotech.com/).
For verification of plasmids, DNA was extracted from bacteria (Qiagen) and appropri-
ate primers were sent to GATC biotec. The data was analyzed using the Snapgene
(http://www.snapgene.com/) software. For verification of PCR products, the PCR re-
action was ran initially in a eletrophoresis gel. Then the amplified pieces were extracted
from the gel and purified (Qiagen). The purified PCR product with the appropriate
primers was sent to GATC biotec and analyzed by Snapgene.
5.3.8 Surveyor assay
Cells were transfected or infected with the gRNA of interest. After three days the cells
were collected and DNA was extracted. The assay was performed according to the man-
ufacturer’s specifications (Integrated DNA Technologies). In brief the assay works as
follows. First a reaction PCR with primers designed adjacent to the targeted site is per-
formed. Next, the amplified piece is dissociated and reannealed by heating and cooling.
The heteroduplex/homoduplex mixer is then treated with Surveyor nuclease. Lastly, an
electrophoresis is performed. Acquisition of extra bands that add to the expected size
of the PCR amplification and thier relative intensity indicates the functionality of the
gRNAs (Fig. 5.3).
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801 
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301 
Actual size
Cut pieces
MCN
Figure 5.3: Surveyor assay. Surveyor nucleas indroduces a double strand break in
the heteroduplexes but not in homoduplexes. A digestion of a piece is observed in the
treated sample (N) in comparison to the control (C). M=1000 kb marker.
5.3.9 Identification of knockout clones via Sanger sequencing
In order to detect knockouts I developed a strategy exploiting Sanger sequencing infor-
mation of double bases. Initially primers are designed adjacent to the targeted site of
the gRNA. The piece is amplified by PCR and the reaction is then loaded in an elec-
trophoresis gel. If there are larger deletions, two bands will appear in the gel. Purifying
those bands will give the sequence information of each allele. In most of the cases, there
is only a single band in the gel. The band is purified and sent for Sanger sequencing
(Materials and Methods 5.3.7). From the data generated, firstly the chromatogram is
read and the region where double bases appear are identified. Both bases are then doc-
umented. Then, sequenced from the reverse primer, the common region is noted. Next,
the common allele is then identified in the double bases from the forward sequence. The
sequences are disentangled and both alleles can be solved according to this information.
In the depicted figure a deletion and an insertion are shown (Fig. 5.4).
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TATATTCATAAGATTCA
TCTTCGTGTCAATTTTGGAATGGGTACCAT...
ACAAGCGTCGCAGTAAGGCGGCTAGACAGG...
AACAAGGTGCGAAGTAAGGAAGGGAGACAGTGCTCTGCTACCT
T T
ACGG
AA A A
TATATTCATAAGATTCA
TATATTCATAAGATTCA
TCTTCCGTTCCATTTTGGCGTCTGTACCAGTCAAAAACAA
TATATTCATAAGATTCATCTTCCGTTCCATTTTGGCGTCTGTACCAGTCAAAAACAA
TATATTCATAAGATTCATCTTCCGTTCCATTTTGGCGTCTGTACCAGTCAAACAAGGTGCGA
TATATTCATAAGATTCAACAAGGTGCGAAGTAAGGAAGGGAGACAGTGCTCTGCTAC
ACAAGGTGCGAAGTAAGGAAGGGAGACAGTGCTCTGCTAC
TCTTCGTGTCAATTTTGGAATGGGTACCAT...
ACAAGCGTCGCAGTAAGGCGGCTAGACAGG...
AACAAGGTGCGAAGTAAGGAAGGGAGACAGTGCTCTGCTACCT
T T
ACGG
AA A A
C C C C C C CT T T T T T T T T T T T T T T T T T GGGGGGGGG AAAAAAAAAAAA
C T TTTC C C CCCG G G G G G G G GGG A A A A A AA AA
AACAAGGTGCGAAGTAAGGAAGGGAGACAGTGCTCTGCTACCT
T
T
AC
G
G A
A A
A
Common in both alleles
Forward primer
Reverse primer
Two bases insersion
Deletion 34 bases
Allele 1
WT
Allele 2
1) Read chromatogram
2) Search and walk-through for common sequenced in mixed peaks
3) Disentangle
4) Solution
Figure 5.4: Strategy to identify knockouts using Sanger sequencing information. 1)
The chromatogram from the Sanger sequenced data is read. The region with the double
read bases is identified and the common sequence of both alleles is noted. 2) The
common allele is then identified from the reverse sequenced and then it is checked in
the double bases of the forward sequence. 3) The information is disentangled according
to the identified sequence. 4) The two alleles are solved according to the generated
information. In this case one allele harbors a deletion of 34 bases and the other allele
harbors an insertion of two bases. Both alleles generate a frame shift in the sequence,
which results into a knockout.
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A.1 Additional Figures
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Figure A.1: Example of PCR validation in recreating the duplication. (a) PCR
strategy to capture the duplication event. (b) PCR on the pool of cells, which were
transfected with the construct versus control. Appearance of three bands are observed
in the pool. The top band represents the expected size of the duplication event with
the insertion of the selection marker as depicted in panel “a”. The second band was
sequenced to carry the duplication with the selection marker but with an aditional
deletion. The third band represents the duplication event without the selection marker.
(c) Individual clones were screened to identify duplication positive clones.
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HCC15,H520, H2170 
virus CRISPRs
lung carcinoma
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Figure A.2: Screening plan for recapitulating rearrangements for IGF2 and IRS4
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B.1 Additional Tables
Table B.1: Clones sequenced for the identification of SCNAs
Gene RPE WT RPETP53-/- RPETP53-/-, hyperploid
NF2 4 4 4
PTPN14 4 4 4
TSC1 NA NA 2
PTEN NA NA 4
AHR 4 4 3
FRYL 3 4 5
SERPINB2 NA NA 2
C6orf222 NA NA 4
RNF7 NA 4 4
TMEM184A NA NA 2
Table B.2: Gene ontology of most significant underrepresented genes. Underrepre-
sented genes are significantly enriched for essential genes. Source Toppgene.
P-value FDR BH Genes from Input Genes in Annotation
translational termination 1.35E-07 1.93E-04 14 95
ribosome biogenesis 1.67E-07 1.93E-04 19 178
RNA processing 2.35E-07 2.06E-04 43 718
mRNA metabolic process 3.54E-07 2.59E-04 40 653
cell cycle 5.31E-05 5.28E-03 67 1611
protein transport 5.42E-05 5.28E-03 62 1457
cell division 5.56E-05 5.30E-03 39 779
translational initiation 6.08E-05 5.67E-03 15 179
mitotic cell cycle 6.48E-05 5.92E-03 44 927
protein folding 9.70E-05 8.68E-03 17 230
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Table B.3: Pathways enriched from the no-selection growth screen top candidates.
Source: Toppgene
Pathway
Name P-adjusted Input genes Annotated
Hippo signaling pathway 1.6E-04 9 154
Developmental Biology 2.2E-03 11 419
neddylation 2.4E-03 3 11
CRMPs in Sema3A signaling 5.4E-03 3 16
the XRE-AhR mediated of drug-metabolizing enzyme expression 5.4E-03 2 3
Inhibition of TSC complex formation by PKB 5.4E-03 2 3
Cell-Cell communication 5.4E-03 6 131
Regulation of Microtubule Cytoskeleton 5.4E-03 4 44
Ubiquitin mediated proteolysis 5.8E-03 6 137
Energy dependent regulation of mTOR by LKB1-AMPK 5.8E-03 3 18
Axon guidance mediated by semaphorins 6.2E-03 3 19
Regulation of Actin Cytoskeleton 6.9E-03 6 147
p53 pathway by glucose deprivation 7.4E-03 3 21
Regulation of actin cytoskeleton 7.4E-03 7 215
Integrated Breast Cancer Pathway 7.7E-03 6 154
Vibrio cholerae infection 7.7E-03 4 54
mTOR Signaling Pathway 8.6E-03 3 23
Signaling events mediated by VEGFR1 and VEGFR2 1.2E-02 4 63
Genes related to PIP3 signaling in cardiac myocytes 1.5E-02 4 67
PKB-mediated events 1.5E-02 3 29
AMPK signaling 1.5E-02 4 68
Adherens junction 1.8E-02 4 73
CXCR4-mediated signaling events 2.0E-02 4 76
Insulin/IGF pathway-protein kinase B signaling cascade 2.0E-02 3 34
Direct p53 effectors 2.0E-02 5 134
CHL1 interactions 2.2E-02 2 9
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Table B.4: gRNAs used in study. The clone name indicates the gene it targets. The
gRNAs were obtained from the GeCKO library except for clones with "CS" (custom
designed).
Gene and clone name gRNA sequence Gene and clone name gRNA sequence
PTPN14_4 CTAGCCGGCCTAGCTGTGCA C6orf222_1 GCCGATGGCCGCTGACACAC
PTPN14_5 GAAATAGCACATACTCTCTG C6orf222_2 CTCCTCGGAGCCGTGTTTCT
PTPN14_6 AGAGTATGTGCTATTTCCTA C6orf222_5 CAGTACCATCCACTTTGATG
NF2_1 CCTGGCTTCTTACGCCGTCC RNF7_1 GCGATACGTGCGCCATCTGC
NF2_5 ATTCCACGGGAAGGAGATCT RNF7_2 CCACCGCGTTCCACTTCTTG
NF2_6 TGAGCCTACCTTGGCCTGGA RNF7_3 TTCAGCTTGACATCTAAGAC
TSC1_4 TTTATCCATCCTCTCGTTAC PTPN14_CS GACCAGGTGATTCGGCTAGC
TSC1_5 ACCTTCGAGGGTCCAGTTCA NF2_CS TCGGATTTCATTCCACGGGA
TSC1_6 ATTCGTTAATCCTGTCCAAG TSC1_CS TTATCCATCCTCTCGTTACT
TSC2_4 GTGGCCTCAACAATCGCATC TSC2_CS GGCGGCATGACGCCTTTCCG
TSC2_5 CCAACGAAGACCTTCACGAA PTEN_CS TATCCAAACATTATTGCTAT
TSC2_6 AGCACGCAGTGGAAGCACTC FRYL_CS TTAGACTTTGTGCTAGACCG
PTEN_2 CCTACCTCTGCAATTAAATT AHR_CS GCCTCCGTTTCTTTCAGTAG
PTEN_4 ACAGATTGTATATCTTGTAA SERPINB2_CS ATGGAGCATCTCGTCCACCA
PTEN_5 ACGCCTTCAAGTCTTTCTGC TMEM184A_CS ATTTGGCAAATACCACGACG
FRYL_2 TACTTCGCACCTTGTTTGAC THRAP3_CS GGAGAAAAAGTCCTCTTCTA
FRYL_5 TATTGTCCAGATCTCTTCAG C6orf222_CS CCCCAAGAAACACGGCTCCG
FRYL_6 CTCTTGATGACATATTCACC RNF7_CS CGATACGTGCGCCATCTGCA
AHR_2 TTGCTGCTCTACAGTTATCC PTPN14_CS GACCAGGTGATTCGGCTAGC
AHR_5 TCCGTTTCTTTCAGTAGGGG NF2_CS CCTGGACGGCGTAAGAAGCC
AHR_6 AGTTGTCACTACAGATGCTT TSC1_CS TTATCCATCCTCTCGTTACT
SERPINB2_1 GATACCTGCAAAATCGCATC TSC2_CS GGCGGCATGACGCCTTTCCG
SERPINB2_2 GGGCAGCACCGAAGACCAGA PTEN_CS TATCCAAACATTATTGCTAT
SERPINB2_5 TGAGAAGTCTGCGAGCTTCC FRYL_CS TTAGACTTTGTGCTAGACCG
TMEM184A_1 GTCTGTCCTAGTGTCCGCAG AHR_CS GCCTCCGTTTCTTTCAGTAG
TMEM184A_2 CTTACTTGAAGTCCCCGTCG SERPINB2_CS ATGGAGCATCTCGTCCACCA
TMEM184A_3 GCGCTCCTACACCGTGCCAC TMEM184A_CS ATTTGGCAAATACCACGACG
THRAP3_1 GATCTTGAACGGCCTCGACG THRAP3_CS GGAGAAAAAGTCCTCTTCTA
THRAP3_2 TGGCCGGCTATCCTTAGAAG C6orf222_CS CCCCAAGAAACACGGCTCCG
THRAP3_3 GACTGCTTATAAAGCAGTCC RNF7_CS CGATACGTGCGCCATCTGCA
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B.2 Additional Figures
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Figure B.1: Quality controls of the RPEWT and RPETP53
-/-,hyperploid trasnformation
screen. (a) The representation of each control guide in replicate was plotted against each
other in order to evaluate the reproducibility of the screen. (b) Principle component
analysis plots indicate that after normalization the replicates are similar. (c) Density
plots before and after normalization. Replicates overlap after normalization.
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Figure B.2: Quality controls of the MCF10AWT and MCF10ATP53
-/-,hyperploid
trasnformation screen. (a) The representation of each control guide in replicate was
plotted against each other in order to evaluate the reproducibility of the screen. The fi-
nal representation shows that the results are not reproducible. (b) Principle component
analysis plots. (c) Density plots.
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Figure B.3: Quality controls of the RPEWT and RPETP53
-/-,hyperploid no-selection
growth screen. (a) The representation of each control guide in replicate was plotted
against each other in order to evaluate the reproducibility of the screen. (b) Principle
component analysis plots indicate that after normalization the replicates are similar. (c)
Density plots before and after normalization. Replicates overlap after normalization.
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Figure B.4: Immunofluorescence of RPETP53
-/-
stained for DNA, AHR and micro-
tubules. (a) AHR antibody is localizing in the centrosomes.Though this is also present
in the knock out clones (data not shown), indicating that this staining is an artifact. (b)
Testing the sigma antibody shows that there is increase expression of AHR in mitotic
cells. This observation needs to still be verified with AHR knock out clones.
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Figure B.5: Ratio of normalized counts of each gRNA for NF2 in all cell lines in the
transformation screen. Only two guides targeting NF2 in the RPETP53
-/-,hyperploid give
higher levels of gRNA representation.
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